Peptide-based molecules in angiogenesis (843 views)
Chem Biol Drug Des (ISSN: 1747-0277, 1747-0285, 1747-0277linking), 2006 Feb; 67(2): 115-126.
Export to BibTeX Export to EndNote
Paper type: Journal Article, Research Support, Non-U. S. Gov'T , Review,
Impact factor: 2.507, 5-year impact factor: 2.479
Url: http://www.scopus.com/inward/record.url?eid=2-s2.0-33745060397&partnerID=40&md5=40af588bda1f456f7e819e3daa0b12c2
Keywords: Angiogenesis, Cancer, Integrins, Ischemia, Peptide, Vascular Endothelial Growth Factor, Acetyllysylleucylthreonyltryptophanylglutaminylglutamylleucyltyrosyl Glutaminylleucyllysyltyrosyllysylglycylisoleucinamide, Alanylserylserylseryltyrosylprolylleucylisoleucylhistidyltryptophanyl Arginylprolyltryptophanylalanylarginine, Alanylthreonyltryptophanylleucylprolylprolylarginine, Angiogenesis Inhibitor, Angiogenesis Modulator, Antibody, Arginylarginyllysylarginylarginylarginine, Arginylthreonylglutamylleucylasparaginylvalylglycylisoleucylaspartyl Phenylalanylasparaginyltryptophanylglutamyltyrosylproline, Asparaginylglycyltyrosylglutamylisoleucylglutamyltryptophanyltyrosylseryl Tryptophanylvalylthreonylhistidylglycylmethionyltyrosine, Becaplermin, Bevacizumab, Cysteinylthreonylthreonylhistidyltryptophanylglycylphenylalanylthreonyl Leucylcysteine, Fibroblast Growth Factor 2, Glutaminyllysylarginyllysylarginyllysyllysylserylarginyltyrosyllysylserine, Glycylaspartylglycyltyrosine, Histidylthreonylmethionyltyrosyltyrosylhistidylhistidyltyrosylglutaminyl Histidylhistidylleucine, Monoclonal Antibody Lm 609, Platelet Derived Growth Factor, Pr 39, Receptor Blocking Agent, Seryltyrosylglycylarginyllysyllysylarginylarginylglutaminylarginylarginyl Arginylprolylglutamine, Serylvalylglutaminylmethionyllysylleucine(dibenzofuran) Isoleucylisoleucylvalyllysylleucylasparaginylaspartic Acid, Tryptophanylhistidylserylaspartylmethionylglutamyltryptophanyltryptophanyl Tyrosylleucylleucylglycine, Unclassified Drug, Unindexed Drug, Valylglutamylprolylasparaginylcysteinylaspartylisoleucylhistidylvalyl Methionyltryptophanylglutamyltryptophanylglutamylcysteinylphenylalanylglutamyl Arginylleucinamide, Vasculotropin, Vasculotropin Receptor, Vitronectin Receptor, Vitronectin Receptor Antagonist, Amino Acid Sequence, Antineoplastic Activity, Cardiovascular Disease, Cell Migration, Cell Proliferation, Circulation, Clinical Trial, Complex Formation, Coronary Artery, Diabetic Foot, Drug Targeting, Electron Microscopy, Embryo Development, Endothelium Cell, Extracellular Matrix, Human, Metastasis, Molecular Biology, Molecular Dynamics, Nonhuman, Peptide Analysis, Pericyte, Priority Journal, Protein Analysis, Protein Expression, Protein Function, Protein Secretion, Protein Structure, Revascularization, Review, Smooth Muscle Fiber, Unspecified Side Effect, Vascular Tissue, Animals, Drug Design, Neovascularization, Pathologic, Structure-Activity Relationship, Serylvalylglutaminylmethionyllysylleucine (dibenzofuran) Isoleucylisoleucylvalyllysylleucylasparaginylaspartic Acid, Integrins Antagonists, Inhibitors Metabolism , Neoplasms Blood Supply Drug Therapy Pathology , Pathologic Drug Therapy Metabolism Pathology , Vascular Endothelial Growth Factor Antagonists, Vascular Endothelial Growth Factor A Antagonists,
Affiliations:
*** IBB - CNR ***
Institute of Biostructure and Bioimaging, CNR and Department of Biological Sciences, University of Napoli 'Federico II', via Mezzocannone 16, 80134 Napoli, Italy
References:
Carmeliet, P., Angiogenesis in health and disease (2003) Nat Med, 9, pp. 653-66
Hanahan, D., Folkman, J., Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis (1996) Cell, 86, pp. 353-364
Carmeliet, P., Jain, R.K., Angiogenesis in cancer and other diseases (2000) Nature, 407, pp. 249-257
Yancopoulos, G.D., Davis, S., Gale, N.W., Rudge, J.S., Wiegand, S.J., Holash, J., Vascular-specific growth factors and blood vessel formation (2000) Nature, 407, pp. 242-248
Bergers, G., Benjamin, L.E., Tumorigenesis and the angiogenic switch (2003) Nat Rev Cancer, 3, pp. 401-410
Ruoslahti, E., Specialization of tumour vasculature (2002) Nat Rev Cancer, 2, pp. 83-90
Helisch, A., Schaper, W., Angiogenesis and arteriogenesis - Not yet for prescription (2000) Z Kardiol, 89, pp. 239-244
Simons, M., Ware, J.A., Therapeutic angiogenesis in cardiovascular disease (2003) Nat Rev Drug Discov, 2, pp. 863-871
Schaper, W., Ito, W.D., Molecular mechanisms of coronary collateral vessel growth (1996) Circ Res, 79, pp. 911-919
Schultz, A., Lavie, L., Hochberg, I., Beyar, R., Stone, T., Skorecki, K., Lavie, P., Levy, A.P., Interindividual heterogeneity in the hypoxic regulation of VEGF: Significance for the development of the coronary artery collateral circulation (1999) Circulation, 100, pp. 547-552
Isner, J.M., Tissue responses to ischemia: Local and remote responses for preserving perfusion of ischemic muscle (2000) J Clin Invest, 106, pp. 615-619
Featherstone, J., Griffiths, S., From the analyst's couch. Drugs that target angiogenesis (2002) Nat Rev Drug Discov, 1, pp. 413-414
Jain, R.K., Carmeliet, P.F., Vessels of death or life (2001) Sci Am, 285, pp. 38-45
Emanueli, C., Madeddu, P., Changing the logic of therapeutic angiogenesis for ischemic disease (2005) Trends Mol Med, 11, pp. 207-216
Lee, C.G., Link, H., Baluk, P., Homer, R.J., Chapoval, S., Bhandari, V., Kang, M.J., Elias, J.A., Vascular endothelial growth factor (VEGF) induces remodeling and enhances TH2-mediated sensitization and inflammation in the lung (2004) Nat Med, 10, pp. 1095-1103
Tozer, G.M., Kanthou, C., Baguley, B.C., Disrupting tumour blood vessels (2005) Nat Rev Cancer, 5, pp. 423-435
Cristofanilli, M., Charnsangavej, C., Hortobagyi, G.N., Angiogenesis modulation in cancer research: Novel clinical approaches (2002) Nat Rev Drug Discov, 1, pp. 415-426
Bouma-Ter Steege, J.C.A., Mayo, K.H., Griffioen, A.W., Angiostatic proteins and peptides (2001) Crit Rev Eukaryot Gene Expr, 11, pp. 319-334
Oku, N., Asai, T., Watanabe, K., Kuromi, K., Nagatsuka, M., Kurohane, K., Kikkawa, H., Taki, T., Anti-neovascular therapy using novel peptides homing to angiogenic vessels (2002) Oncogene, 21, pp. 2662-2669
Asai, T., Nagatsuka, M., Kuromi, K., Yamakawa, S., Kurohane, K., Ogino, K., Tanaka, M., Oku, N., Suppression of tumor growth by novel peptides homing to tumor-derived new blood vessels (2002) FEBS Lett, 510, pp. 206-210
Mayo, K.H., Dings, R.P., Flader, C., Nesmelova, I., Hargittai, B., Van Der Schaft, D.W., Van Eijk, L.I., Griffioen, A.W., Design of a partial peptide mimetic of anginex with antiangiogenic and anticancer activity (2003) J Biol Chem, 278, pp. 45746-45752
Blaskovich, M.A., Lin, Q., Delarue, F.L., Sun, J., Park, H.S., Coppola, D., Hamilton, A.D., Sebti, S.M., Design of GFB-111, a platelet-derived growth factor binding molecule with antiangiogenic and anticancer activity against human tumors in mice (2000) Nat Biotechnol, 18, pp. 1065-1070
Koivunen, E., Arap, W., Valtanen, H., Rainisalo, A., Medina, O.P., Heikkila, P., Kantor, C., Pasqualini, R., Tumor targeting with a selective gelatinase inhibitor (1999) Nat Biotechnol, 17, pp. 768-774
Li, J., Post, M., Volk, R., Gao, Y., Li, M., Metais, C., Sato, K., Simons, M., PR39, a peptide regulator of angiogenesis (2000) Nat Med, 6, pp. 49-55
Hamada, Y., Nokihara, K., Okazaki, M., Fujitani, W., Matsumoto, T., Matsuo, M., Umakoshi, Y., Matsuura, N., Angiogenic activity of osteopontin-derived peptide SVVYGLR (2003) Biochem Biophys Res Commun, 310, pp. 153-157
Ferrara, N., VEGF: An update on biological and therapeutic aspects (2000) Curr Opin Biotechnol, 11, pp. 617-624
Ferrara, N., Gerber, H.P., Lecouter, J., The biology of VEGF and its receptors (2003) Nat Med, 9, pp. 669-676
Ferrara, N., Davis-Smyth, T., The biology of vascular endothelial growth factor (1997) Endocr Rev, 18, pp. 4-25
Autiero, M., Waltenberger, J., Communi, D., Kranz, A., Moons, L., Lambrechts, D., Kroll, J., Mayr-Beyrle, U., Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1 (2003) Nat Med, 9, pp. 936-943
Brogi, E., Schatteman, G., Wu, T., Kim, E.A., Varticovski, L., Keyt, B., Isner, J.M., Hypoxia-induced paracrine regulation of vascular endothelial growth factor receptor expression (1996) J Clin Invest, 97, pp. 469-476
Abedi, H., Zachary, I., Vascular endothelial growth factor stimulates tyrosine phosphorylation and recruitment to new focal adhesions of focal adhesion kinase and paxillin in endothelial cells (1997) J Biol Chem, 272, pp. 15442-15451
Muller, Y.A., Li, B., Christinger, H.W., Wells, J.A., Cunningham, B.C., De Vos, A.M., Vascular endothelial growth factor: Crystal structure and functional mapping of the kinase domain receptor binding site (1997) Proc Natl Acad Sci U S a, 94, pp. 7192-7197
Muller, Y.A., Christinger, H.W., Keyt, B.A., De Vos, A.M., The crystal structure of vascular endothelial growth factor (VEGF) refined to 1.93 a resolution: Multiple copy flexibility and receptor binding (1997) Structure, 5, pp. 1325-1338
Wiesmann, C., Christinger, H.W., Cochran, A.G., Cunningham, B.C., Fairbrother, W.J., Keenan, C.J., Meng, G., De Vos, A.M., Crystal structure of the complex between VEGF and a receptor-blocking peptide (1998) Biochemistry, 37, pp. 17765-17772
Pan, B., Li, B., Russell, S.J., Tom, J.Y., Cochran, A.G., Fairbrother, W.J., Solution structure of a phage-derived peptide antagonist in complex with vascular endothelial growth factor (2002) J Mol Biol, 316, pp. 769-787
Muller, Y.A., Chen, Y., Christinger, H.W., Li, B., Cunningham, B.C., Lowman, H.B., De Vos, A.M., VEGF and the Fab fragment of a humanized neutralizing antibody: Crystal structure of the complex at 2.4 a resolution and mutational analysis of the interface (1998) Structure, 6, pp. 1153-1167
Wiesmann, C., Fuh, G., Christinger, H.W., Eigenbrot, C., Wells, J.A., De Vos, A.M., Crystal structure at 1.7 a resolution of VEGF in complex with domain 2 of the Flt-1 receptor (1997) Cell, 91, pp. 695-704
Keyt, B.A., Nguyen, H.V., Berleau, L.T., Duarte, C.M., Park, J., Chen, H., Ferrara, N., Identification of vascular endothelial growth factor determinants for binding KDR and FLT-1 receptors. Generation of receptor-selective VEGF variants by site-directed mutagenesis (1996) J Biol Chem, 271, pp. 5638-5646
Ferrara, N., Hillan, K.J., Gerber, H.P., Novotny, W., Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer (2004) Nat Rev Drug Discov, 3, pp. 391-400
Cooke, S.P., Boxer, G.M., Lawrence, L., Pedley, R.B., Spencer, D.I., Begent, R.H., Chester, K.A., A strategy for antitumor vascular therapy by targeting the vascular endothelial growth factor: Receptor complex (2001) Cancer Res, 61, pp. 3653-3659
Lu, D., Shen, J., Vil, M.D., Zhang, H., Jimenez, X., Bohlen, P., Witte, L., Zhu, Z., Tailoring in vitro selection for a picomolar affinity human antibody directed against vascular endothelial growth factor receptor 2 for enhanced neutralizing activity (2003) J Biol Chem, 278, pp. 43496-43507
Prewett, M., Huber, J., Li, Y., Santiago, A., O'Connor, W., King, K., Overholser, J., Hicklin, D.J., Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors (1999) Cancer Res, 59, pp. 5209-5218
Willett, C.G., Boucher, Y., Di Tomaso, E., Duda, D.G., Munn, L.L., Tong, R.T., Chung, D.C., Fischman, A.J., Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer (2004) Nat Med, 10, pp. 145-147
Underiner, T.L., Ruggeri, B., Gingrich, D.E., Development of vascular endothelial growth factor receptor (VEGFR) kinase inhibitors as anti-angiogenic agents in cancer therapy (2004) Curr Med Chem, 11, pp. 731-745
Sun, J., Wang, D.A., Jain, R.K., Carie, A., Paquette, S., Ennis, E., Blaskovich, M.A., Sebti, S.M., Inhibiting angiogenesis and tumorigenesis by a synthetic molecule that blocks binding of both VEGF and PDGF to their receptors (2005) Oncogene, 24, pp. 4701-4709
Sun, J., Blaskovich, M.A., Jain, R.K., Delarue, F., Paris, D., Brem, S., Wotoczek-Obadia, M., Sebti, S.M., Blocking angiogenesis and tumorigenesis with GFA-116, a synthetic molecule that inhibits binding of vascular endothelial growth factor to its receptor (2004) Cancer Res, 64, pp. 3586-3592
Holash, J., Davis, S., Papadopoulos, N., Croll, S.D., Ho, L., Russell, M., Boland, P., Fandl, J.P., VEGF-Trap: A VEGF blocker with potent antitumor effects (2002) Proc Natl Acad Sci U S a, 99, pp. 11393-11398
Kim, E.S., Serur, A., Huang, J., Manley, C.A., McCrudden, K.W., Frischer, J.S., Soffer, S.Z., Yamashiro, D.J., Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma (2002) Proc Natl Acad Sci U S a, 99, pp. 11399-11404
Takei, Y., Kadomatsu, K., Yuzawa, Y., Matsuo, S., Muramatsu, T., A small interfering RNA targeting vascular endothelial growth factor as cancer therapeutics (2004) Cancer Res, 64, pp. 3365-3370
Niethammer, A.G., Xiang, R., Becker, J.C., Wodrich, H., Pertl, U., Karsten, G., Eliceiri, B.P., Reisfeld, R.A., A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth (2002) Nat Med, 8, pp. 1369-1375
Fairbrother, W.J., Christinger, H.W., Cochran, A.G., Fuh, G., Keenan, C.J., Quan, C., Shriver, S.K., Cunningham, B.C., Novel peptides selected to bind vascular endothelial growth factor target the receptor-binding site (1998) Biochemistry, 37, pp. 17754-17764
Binetruy-Tournaire, R., Demangel, C., Malavaud, B., Vassy, R., Rouyre, S., Kraemer, M., Plouet, J., Mazie, J.C., Identification of a peptide blocking vascular endothelial growth factor (VEGF)-mediated angiogenesis (2000) EMBO J, 19, pp. 1525-1533
El-Mousawi, M., Tchistiakova, L., Yurchenko, L., Pietrzynski, G., Moreno, M., Stanimirovic, D., Ahmad, D., Alakhov, V., A vascular endothelial growth factor high affinity receptor 1-specific peptide with antiangiogenic activity identified using a phage display peptide library (2003) J Biol Chem, 278, pp. 46681-46691
Hetian, L., Ping, A., Shumei, S., Xiaoying, L., Luowen, H., Jian, W., Lin, M., Chengchao, S., A novel peptide isolated from a phage display library inhibits tumor growth and metastasis by blocking the binding of vascular endothelial growth factor to its kinase domain receptor (2002) J Biol Chem, 277, pp. 43137-43142
An, P., Lei, H., Zhang, J., Song, S., He, L., Jin, G., Liu, X., Shou, C., Suppression of tumor growth and metastasis by a VEGFR-1 antagonizing peptide identified from a phage display library (2004) Int J Cancer, 111, pp. 165-173
Zilberberg, L., Shinkaruk, S., Lequin, O., Rousseau, B., Hagedorn, M., Costa, F., Caronzolo, D., Bello, L., Structure and inhibitory effects on angiogenesis and tumor development of a new vascular endothelial growth inhibitor (2003) J Biol Chem, 278, pp. 35564-35573
Bae, D.G., Gho, Y.S., Yoon, W.H., Chae, C.B., Arginine-rich anti-vascular endothelial growth factor peptides inhibit tumor growth and metastasis by blocking angiogenesis (2000) J Biol Chem, 275, pp. 13588-13596
Jia, H., Jezequel, S., Lohr, M., Shaikh, S., Davis, D., Soker, S., Selwood, D., Zachary, I., Peptides encoded by exon 6 of VEGF inhibit endothelial cell biological responses and angiogenesis induced by VEGF (2001) Biochem Biophys Res Commun, 283, pp. 164-173
Piossek, C., Schneider-Mergener, J., Schirner, M., Vakalopoulou, E., Germeroth, L., Thierauch, K.H., Vascular endothelial growth factor (VEGF) receptor II-derived peptides inhibit VEGF (1999) J Biol Chem, 274, pp. 5612-5619
Albini, A., Soldi, R., Giunciuglio, D., Giraudo, E., Benelli, R., Primo, L., Noonan, D., Bussolino, F., The angiogenesis induced by HIV-1 tat protein is mediated by the Flk-1/KDR receptor on vascular endothelial cells (1996) Nat Med, 2, pp. 1371-1375
D'Andrea, L.D., Iaccarino, G., Fattorusso, R., Sorriento, D., Carannante, C., Capasso, D., Trimarco, B., Pedone, C., Targeting angiogenesis: Structural characterization and biological properties of a de novo engineered VEGF mimicking peptide (2005) Proc Natl Acad Sci U S a, 102, pp. 14215-14220
Giancotti, F.G., Ruoslahti, E., Integrin signaling (1999) Science, 285, pp. 1028-1032
Van Der Flier, A., Sonnenberg, A., Function and interactions of integrins (2001) Cell Tissue Res, 305, pp. 285-298
Brooks, P.C., Clark, R.A., Cheresh, D.A., Requirement of vascular integrin alpha v beta 3 for angiogenesis (1994) Science, 264, pp. 569-571
Schlaepfer, D.D., Hauck, C.R., Sieg, D.J., Signaling through focal adhesion kinase (1999) Prog Biophys Mol Biol, 71, pp. 435-478
Longhurst, C.M., Jennings, L.K., Integrin-mediated signal transduction (1998) Cell Mol Life Sci, 54, pp. 514-526
Stupack, D.G., Puente, X.S., Boutsaboualoy, S., Storgard, C.M., Cheresh, D.A., Apoptosis of adherent cells by recruitment of caspase-8 to unligated integrins (2001) J Cell Biol, 155, pp. 459-470
Xiong, J.P., Stehle, T., Diefenbach, B., Zhang, R., Dunker, R., Scott, D.L., Joachimiak, A., Arnaout, M.A., Crystal structure of the extracellular segment of integrin alpha Vbeta3 (2001) Science, 294, pp. 339-345
Gottschalk, K.E., Gunther, R., Kessler, H., A three-state mechanism of integrin activation and signal transduction for integrin alpha(v)beta(3) (2002) Chembiochem, 3, pp. 470-473
Pierschbacher, M.D., Ruoslahti, E., Variants of the cell recognition site of fibronectin that retain attachment-promoting activity (1984) Proc Natl Acad Sci U S a, 81, pp. 5985-5988
Ruoslahti, E., Pierschbacher, M.D., New perspectives in cell adhesion: RGD and integrins (1987) Science, 238, pp. 491-497
Albelda, S.M., Buck, C.A., Integrins and other cell adhesion molecules (1990) FASEB J, 4, pp. 2868-2880
Humphries, M.J., The molecular basis and specificity of integrin-ligand interactions (1990) J Cell Sci, 97 (4), pp. 585-592
Hautanen, A., Gailit, J., Mann, D.M., Ruoslahti, E., Effects of modifications of the RGD sequence and its context on recognition by the fibronectin receptor (1989) J Biol Chem, 264, pp. 1437-1442
Miller, W.H., Keenan, R.M., Willette, R.N., Lark, M.W., Identification and in vivo efficacy of small-molecule antagonists of integrin alphavbeta3 (the vitronectin receptor) (2000) Drug Discov Today, 5, pp. 397-408
Marugan, J.J., Manthey, C., Anaclerio, B., Lafrance, L., Lu, T., Markotan, T., Leonard, K.A., Tomczuk, B., Design, synthesis, and biological evaluation of novel potent and selective alphavbeta3/alphavbeta5 integrin dual inhibitors with improved bioavailability. Selection of the molecular core (2005) J Med Chem, 48, pp. 926-934
Goodman, S.L., Holzemann, G., Sulyok, G.A., Kessler, H., Nanomolar small molecule inhibitors for alphav(beta)6, alphav(beta)5, and alphav(beta)3 integrins (2002) J Med Chem, 45, pp. 1045-1051
Haubner, R., Gratias, R., Diefenbach, B., Goodman, S., Joachimiak, A., Kessler, H., Structural and functional aspects of RGD-containing cyclic pentapeptides as highly potent and selective integrin alphaVbeta3 antagonists (1996) J Am Chem Soc, 118, pp. 7461-7472
Mitjans, F., Meyer, T., Fittschen, C., Goodman, S., Jonczyk, A., Marshall, J.F., Reyes, G., Piulats, J., In vivo therapy of malignant melanoma by means of antagonists of alphav integrins (2000) Int J Cancer, 87, pp. 716-723
Dechantsreiter, M.A., Planker, E., Matha, B., Lohof, E., Holzemann, G., Jonczyk, A., Goodman, S.L., Kessler, H., N-Methylated cyclic RGD peptides as highly active and selective alpha(V)beta(3) integrin antagonists (1999) J Med Chem, 42, pp. 3033-3040
Sulyok, G.A., Gibson, C., Goodman, S.L., Holzemann, G., Wiesner, M., Kessler, H., Solid-phase synthesis of a nonpeptide RGD mimetic library: New selective alphavbeta3 integrin antagonists (2001) J Med Chem, 44, pp. 1938-1950
Belvisi, L., Bernardi, A., Checchia, A., Manzoni, L., Potenza, D., Scolastico, C., Castorina, M., Pisano, C., Potent integrin antagonists from a small library of RGD-including cyclic pseudopeptides (2001) Org Lett, 3, pp. 1001-1004
Posey, J.A., Khazaeli, M.B., Delgrosso, A., Saleh, M.N., Lin, C.Y., Huse, W., Lobuglio, A.F., A pilot trial of Vitaxin, a humanized anti-vitronectin receptor (anti alpha v beta 3) antibody in patients with metastatic cancer (2001) Cancer Biother Radiopharm, 16, pp. 125-132
Kessler, H., Peptide conformations: Part 16. Solid-state carbon-13 NMR spectra of cyclotriprolines (1982) Angew Chem Int Ed Engl, 94, pp. 509-520
Aumailley, M., Gurrath, M., Muller, G., Calvete, J., Timpl, R., Kessler, H., Arg-Gly-Asp constrained within cyclic pentapeptides. Strong and selective inhibitors of cell adhesion to vitronectin and laminin fragment P1 (1991) FEBS Lett, 291, pp. 50-54
Pfaff, M., Tangemann, K., Muller, B., Gurrath, M., Muller, G., Kessler, H., Timpl, R., Engel, J., Selective recognition of cyclic RGD peptides of NMR defined conformation by alpha IIb beta 3, alpha V beta 3, and alpha 5 beta 1 integrins (1994) J Biol Chem, 269, pp. 20233-20238
Haubner, R., Schmitt, W., Holzemann, G., Goodman, S., Jonczyk, A., Kessler, H., Cyclic RGD peptides containing beta-turn mimetics (1996) J Am Chem Soc, 118, pp. 7881-7891
Haubner, R., Finsinger, D., Kessler, H., Stereoisomeric peptide libraries and peptidomimetics for designing selective inhibitors of the avb3 integrin for a new cancer therapy (1997) Angew Chem Int Ed Engl, 36, pp. 1374-1389
Kawaguchi, M., Hosotani, R., Ohishi, S., Fujii, N., Tulachan, S.S., Koizumi, M., Toyoda, E., Imamura, M., A novel synthetic Arg-Gly-Asp-containing peptide cyclo(-RGDf = V-) is the potent inhibitor of angiogenesis (2001) Biochem Biophys Res Commun, 288, pp. 711-717
Coleman, P.J., Brashear, K.M., Hunt, C.A., Hoffman, W.F., Hutchinson, J.H., Breslin, M.J., McVean, C.A., Ma, B., Non-peptide alpha(v)beta(3) antagonists. identification of potent RGD mimetics incorporating novel beta-amino acids as aspartic acid replacements (2002) Bioorg Med Chem Lett, 3, pp. 31-34
Kumar, C.C., Malkowski, M., Yin, Z., Tanghetti, E., Yaremko, B., Nechuta, T., Varner, J., Armstrong, L., Inhibition of angiogenesis and tumor growth by SCH221153, a dual alpha(v)beta3 and alpha(v)beta5 integrin receptor antagonist (2001) Cancer Res, 61, pp. 2232-2238
Urbahns, K., Harter, M., Albers, M., Schmidt, D., Stelte-Ludwig, B., Bruggemeier, U., Vaupel, A., Gerdes, C., Biphenyls as potent vitronectin receptor antagonists (2002) Bioorg Med Chem Lett, 12, pp. 205-208
Van Well, R.M., Overkleeft, H.S., Van Der Marel, G.A., Bruss, D., Thibault, G., De Groot, P.G., Van Boom, J.H., Overhand, M., Solid-phase synthesis of cyclic RGD-furanoid sugar amino acid peptides as integrin inhibitors (2003) Bioorg Med Chem Lett, 13, pp. 331-334
Manthey, C., Lee, Y., Wang, A., Crysler, C., Zhao, S., Bone, R.F., Tomczuk, B.E., Characterization of O-guanidines as novel alphaVbeta3 inhibitors (2001) Proc Am Assoc Cancer Res, 42, p. 368
Marugan, J.J., Haslow, K.D., Crysler, C., Design, synthesis, and biochemical evaluation of novel alpha V beta 3 integrin ligands (2004) Bioorg Med Chem Lett, 14, pp. 4553-4555
Eskens, F.A., Dumez, H., Hoekstra, R., Perschl, A., Brindley, C., Bottcher, S., Wynendaele, W., Van Oosterom, A.T., Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins alphavbeta3 and alphavbeta5 in patients with advanced solid tumours (2003) Eur J Cancer, 39, pp. 917-926
Pasqualini, R., Koivunen, E., Ruoslahti, E., Alpha v integrins as receptors for tumor targeting by circulating ligands (1997) Nat Biotechnol, 15, pp. 542-546
Gante, J., Peptidomimetics - Tailored enzyme inhibitors (1994) Angew Chem Int Ed Engl, 33, pp. 1699-1720
Gante, J., Azapeptides (1989) Synthesis, pp. 405-413
Gould, R.J., Polokoff, M.A., Friedman, P.A., Huang, T.F., Holt, J.C., Cook, J.J., Niewiarowski, S., Disintegrins: A family of integrin inhibitory proteins from viper venoms (1990) Proc Soc Exp Biol Med, 195, pp. 168-171
Niewiarowski, S., McLane, M.A., Kloczewiak, M., Stewart, G.J., Disintegrins and other naturally occurring antagonists of platelet fibrinogen receptors (1994) Semin Hematol, 31, pp. 289-300
Gan, Z.R., Gould, R.J., Jacobs, J.W., Friedman, P.A., Polokoff, M.A., Echistatin. a potent platelet aggregation inhibitor from the venom of the viper, Echis carinatus (1988) J Biol Chem, 263, pp. 19827-19832
Marcinkiewicz, C., Rosenthal, L.A., Mosser, D.M., Kunicki, T.J., Niewiarowski, S., Immunological characterization of eristostatin and echistatin binding sites on alpha IIb beta 3 and alpha V beta 3 integrins (1996) Biochem J, 317 (3), pp. 817-825
Zartler, E.R., Shapiro, M.J., Fragonomics: Fragment-based drug discovery (2005) Curr Opin Chem Biol, 9, pp. 366-370
Yamada, K.M., Even-Ram, S., Integrin regulation of growth factor receptors (2002) Nat Cell Biol, 4, pp. E75-E76
Brooks, P.C., Stromblad, S., Sanders, L.C., Von Schalscha, T.L., Aimes, R.T., Stetler-Stevenson, W.G., Quigley, J.P., Cheresh, D.A., Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3 (1996) Cell, 85, pp. 683-693
De, S., Razorenova, O., McCabe, N.P., O'Toole, T., Qin, J., Byzova, T.V., VEGF-integrin interplay controls tumor growth and vascularization (2005) Proc Natl Acad Sci U S a, 102, pp. 7589-7594
Mizukami, Y., Jo, W.S., Duerr, E.M., Gala, M., Li, J., Zhang, X., Zimmer, M.A., Chung, D.C., Induction of interleukin-8 preserves the angiogenic response in HIF-1alpha-deficient colon cancer cells (2005) Nat Med, 11, pp. 992-997
Carmeliet, P., VEGF gene therapy: Stimulating angiogenesis or angiomagenesis (2000) Nat Med, 6, pp. 1102-1103
Weis, S.M., Cheresh, D.A., Pathophysiological consequences of VEGF-induced vascular permeability (2005) Nature, 437, pp. 497-504
Liu, S., Edwards, D.S., 99mTc-labeled small peptides as diagnostic radiopharmaceuticals (1999) Chem Rev, 99, pp. 2235-2268
Li, S., Peck-Radosavljevic, M., Kienast, O., Preitfellner, J., Hamilton, G., Kurtaran, A., Pirich, C., Dudczak, R., Imaging gastrointestinal tumours using vascular endothelial growth factor-165 (VEGF165) receptor scintigraphy (2003) Ann Oncol, 14, pp. 1274-1277
Haubner, R., Wester, H.J., Radiolabeled tracers for imaging of tumor angiogenesis and evaluation of anti-angiogenic therapies (2004) Curr Pharm des, 10, pp. 1439-1455
Miller, J.C., Pien, H.H., Sahani, D., Sorensen, A.G., Thrall, J.H., Imaging angiogenesis: Applications and potential for drug development (2005) J Natl Cancer Inst, 97, pp. 172-187
Yancopoulos, G. D., Davis, S., Gale, N. W., Rudge, J. S., Wiegand, S. J., Holash, J., Vascular-specific growth factors and blood vessel formation (2000) Nature, 407, pp. 242-248
Isner, J. M., Tissue responses to ischemia: Local and remote responses for preserving perfusion of ischemic muscle (2000) J Clin Invest, 106, pp. 615-619
Jain, R. K., Carmeliet, P. F., Vessels of death or life (2001) Sci Am, 285, pp. 38-45
Lee, C. G., Link, H., Baluk, P., Homer, R. J., Chapoval, S., Bhandari, V., Kang, M. J., Elias, J. A., Vascular endothelial growth factor (VEGF) induces remodeling and enhances TH2-mediated sensitization and inflammation in the lung (2004) Nat Med, 10, pp. 1095-1103
Tozer, G. M., Kanthou, C., Baguley, B. C., Disrupting tumour blood vessels (2005) Nat Rev Cancer, 5, pp. 423-435
Mayo, K. H., Dings, R. P., Flader, C., Nesmelova, I., Hargittai, B., Van Der Schaft, D. W., Van Eijk, L. I., Griffioen, A. W., Design of a partial peptide mimetic of anginex with antiangiogenic and anticancer activity (2003) J Biol Chem, 278, pp. 45746-45752
Blaskovich, M. A., Lin, Q., Delarue, F. L., Sun, J., Park, H. S., Coppola, D., Hamilton, A. D., Sebti, S. M., Design of GFB-111, a platelet-derived growth factor binding molecule with antiangiogenic and anticancer activity against human tumors in mice (2000) Nat Biotechnol, 18, pp. 1065-1070
Muller, Y. A., Li, B., Christinger, H. W., Wells, J. A., Cunningham, B. C., De Vos, A. M., Vascular endothelial growth factor: Crystal structure and functional mapping of the kinase domain receptor binding site (1997) Proc Natl Acad Sci U S a, 94, pp. 7192-7197
Muller, Y. A., Christinger, H. W., Keyt, B. A., De Vos, A. M., The crystal structure of vascular endothelial growth factor (VEGF) refined to 1. 93 a resolution: Multiple copy flexibility and receptor binding (1997) Structure, 5, pp. 1325-1338
Muller, Y. A., Chen, Y., Christinger, H. W., Li, B., Cunningham, B. C., Lowman, H. B., De Vos, A. M., VEGF and the Fab fragment of a humanized neutralizing antibody: Crystal structure of the complex at 2. 4 a resolution and mutational analysis of the interface (1998) Structure, 6, pp. 1153-1167
Keyt, B. A., Nguyen, H. V., Berleau, L. T., Duarte, C. M., Park, J., Chen, H., Ferrara, N., Identification of vascular endothelial growth factor determinants for binding KDR and FLT-1 receptors. Generation of receptor-selective VEGF variants by site-directed mutagenesis (1996) J Biol Chem, 271, pp. 5638-5646
Cooke, S. P., Boxer, G. M., Lawrence, L., Pedley, R. B., Spencer, D. I., Begent, R. H., Chester, K. A., A strategy for antitumor vascular therapy by targeting the vascular endothelial growth factor: Receptor complex (2001) Cancer Res, 61, pp. 3653-3659
Willett, C. G., Boucher, Y., Di Tomaso, E., Duda, D. G., Munn, L. L., Tong, R. T., Chung, D. C., Fischman, A. J., Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer (2004) Nat Med, 10, pp. 145-147
Underiner, T. L., Ruggeri, B., Gingrich, D. E., Development of vascular endothelial growth factor receptor (VEGFR) kinase inhibitors as anti-angiogenic agents in cancer therapy (2004) Curr Med Chem, 11, pp. 731-745
Sun, J., Wang, D. A., Jain, R. K., Carie, A., Paquette, S., Ennis, E., Blaskovich, M. A., Sebti, S. M., Inhibiting angiogenesis and tumorigenesis by a synthetic molecule that blocks binding of both VEGF and PDGF to their receptors (2005) Oncogene, 24, pp. 4701-4709
Kim, E. S., Serur, A., Huang, J., Manley, C. A., McCrudden, K. W., Frischer, J. S., Soffer, S. Z., Yamashiro, D. J., Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma (2002) Proc Natl Acad Sci U S a, 99, pp. 11399-11404
Niethammer, A. G., Xiang, R., Becker, J. C., Wodrich, H., Pertl, U., Karsten, G., Eliceiri, B. P., Reisfeld, R. A., A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth (2002) Nat Med, 8, pp. 1369-1375
Bae, D. G., Gho, Y. S., Yoon, W. H., Chae, C. B., Arginine-rich anti-vascular endothelial growth factor peptides inhibit tumor growth and metastasis by blocking angiogenesis (2000) J Biol Chem, 275, pp. 13588-13596
D'Andrea, L. D., Iaccarino, G., Fattorusso, R., Sorriento, D., Carannante, C., Capasso, D., Trimarco, B., Pedone, C., Targeting angiogenesis: Structural characterization and biological properties of a de novo engineered VEGF mimicking peptide (2005) Proc Natl Acad Sci U S a, 102, pp. 14215-14220
Giancotti, F. G., Ruoslahti, E., Integrin signaling (1999) Science, 285, pp. 1028-1032
Brooks, P. C., Clark, R. A., Cheresh, D. A., Requirement of vascular integrin alpha v beta 3 for angiogenesis (1994) Science, 264, pp. 569-571
Schlaepfer, D. D., Hauck, C. R., Sieg, D. J., Signaling through focal adhesion kinase (1999) Prog Biophys Mol Biol, 71, pp. 435-478
Longhurst, C. M., Jennings, L. K., Integrin-mediated signal transduction (1998) Cell Mol Life Sci, 54, pp. 514-526
Stupack, D. G., Puente, X. S., Boutsaboualoy, S., Storgard, C. M., Cheresh, D. A., Apoptosis of adherent cells by recruitment of caspase-8 to unligated integrins (2001) J Cell Biol, 155, pp. 459-470
Xiong, J. P., Stehle, T., Diefenbach, B., Zhang, R., Dunker, R., Scott, D. L., Joachimiak, A., Arnaout, M. A., Crystal structure of the extracellular segment of integrin alpha Vbeta3 (2001) Science, 294, pp. 339-345
Gottschalk, K. E., Gunther, R., Kessler, H., A three-state mechanism of integrin activation and signal transduction for integrin alpha (v) beta (3) (2002) Chembiochem, 3, pp. 470-473
Pierschbacher, M. D., Ruoslahti, E., Variants of the cell recognition site of fibronectin that retain attachment-promoting activity (1984) Proc Natl Acad Sci U S a, 81, pp. 5985-5988
Albelda, S. M., Buck, C. A., Integrins and other cell adhesion molecules (1990) FASEB J, 4, pp. 2868-2880
Humphries, M. J., The molecular basis and specificity of integrin-ligand interactions (1990) J Cell Sci, 97 (4), pp. 585-592
Miller, W. H., Keenan, R. M., Willette, R. N., Lark, M. W., Identification and in vivo efficacy of small-molecule antagonists of integrin alphavbeta3 (the vitronectin receptor) (2000) Drug Discov Today, 5, pp. 397-408
Marugan, J. J., Manthey, C., Anaclerio, B., Lafrance, L., Lu, T., Markotan, T., Leonard, K. A., Tomczuk, B., Design, synthesis, and biological evaluation of novel potent and selective alphavbeta3/alphavbeta5 integrin dual inhibitors with improved bioavailability. Selection of the molecular core (2005) J Med Chem, 48, pp. 926-934
Goodman, S. L., Holzemann, G., Sulyok, G. A., Kessler, H., Nanomolar small molecule inhibitors for alphav (beta) 6, alphav (beta) 5, and alphav (beta) 3 integrins (2002) J Med Chem, 45, pp. 1045-1051
Dechantsreiter, M. A., Planker, E., Matha, B., Lohof, E., Holzemann, G., Jonczyk, A., Goodman, S. L., Kessler, H., N-Methylated cyclic RGD peptides as highly active and selective alpha (V) beta (3) integrin antagonists (1999) J Med Chem, 42, pp. 3033-3040
Sulyok, G. A., Gibson, C., Goodman, S. L., Holzemann, G., Wiesner, M., Kessler, H., Solid-phase synthesis of a nonpeptide RGD mimetic library: New selective alphavbeta3 integrin antagonists (2001) J Med Chem, 44, pp. 1938-1950
Posey, J. A., Khazaeli, M. B., Delgrosso, A., Saleh, M. N., Lin, C. Y., Huse, W., Lobuglio, A. F., A pilot trial of Vitaxin, a humanized anti-vitronectin receptor (anti alpha v beta 3) antibody in patients with metastatic cancer (2001) Cancer Biother Radiopharm, 16, pp. 125-132
Coleman, P. J., Brashear, K. M., Hunt, C. A., Hoffman, W. F., Hutchinson, J. H., Breslin, M. J., McVean, C. A., Ma, B., Non-peptide alpha (v) beta (3) antagonists. identification of potent RGD mimetics incorporating novel beta-amino acids as aspartic acid replacements (2002) Bioorg Med Chem Lett, 3, pp. 31-34
Kumar, C. C., Malkowski, M., Yin, Z., Tanghetti, E., Yaremko, B., Nechuta, T., Varner, J., Armstrong, L., Inhibition of angiogenesis and tumor growth by SCH221153, a dual alpha (v) beta3 and alpha (v) beta5 integrin receptor antagonist (2001) Cancer Res, 61, pp. 2232-2238
Van Well, R. M., Overkleeft, H. S., Van Der Marel, G. A., Bruss, D., Thibault, G., De Groot, P. G., Van Boom, J. H., Overhand, M., Solid-phase synthesis of cyclic RGD-furanoid sugar amino acid peptides as integrin inhibitors (2003) Bioorg Med Chem Lett, 13, pp. 331-334
Marugan, J. J., Haslow, K. D., Crysler, C., Design, synthesis, and biochemical evaluation of novel alpha V beta 3 integrin ligands (2004) Bioorg Med Chem Lett, 14, pp. 4553-4555
Eskens, F. A., Dumez, H., Hoekstra, R., Perschl, A., Brindley, C., Bottcher, S., Wynendaele, W., Van Oosterom, A. T., Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins alphavbeta3 and alphavbeta5 in patients with advanced solid tumours (2003) Eur J Cancer, 39, pp. 917-926
Gould, R. J., Polokoff, M. A., Friedman, P. A., Huang, T. F., Holt, J. C., Cook, J. J., Niewiarowski, S., Disintegrins: A family of integrin inhibitory proteins from viper venoms (1990) Proc Soc Exp Biol Med, 195, pp. 168-171
Gan, Z. R., Gould, R. J., Jacobs, J. W., Friedman, P. A., Polokoff, M. A., Echistatin. a potent platelet aggregation inhibitor from the venom of the viper, Echis carinatus (1988) J Biol Chem, 263, pp. 19827-19832
Zartler, E. R., Shapiro, M. J., Fragonomics: Fragment-based drug discovery (2005) Curr Opin Chem Biol, 9, pp. 366-370
Yamada, K. M., Even-Ram, S., Integrin regulation of growth factor receptors (2002) Nat Cell Biol, 4, pp. E75-E76
Brooks, P. C., Stromblad, S., Sanders, L. C., Von Schalscha, T. L., Aimes, R. T., Stetler-Stevenson, W. G., Quigley, J. P., Cheresh, D. A., Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3 (1996) Cell, 85, pp. 683-693
Weis, S. M., Cheresh, D. A., Pathophysiological consequences of VEGF-induced vascular permeability (2005) Nature, 437, pp. 497-504
Miller, J. C., Pien, H. H., Sahani, D., Sorensen, A. G., Thrall, J. H., Imaging angiogenesis: Applications and potential for drug development (2005) J Natl Cancer Inst, 97, pp. 172-187
Chem Biol Drug Des (ISSN: 1747-0277, 1747-0285, 1747-0277linking), 2006 Feb; 67(2): 115-126.
Export to BibTeX Export to EndNote
Paper type: Journal Article, Research Support, Non-U. S. Gov'T , Review,
Impact factor: 2.507, 5-year impact factor: 2.479
Url: http://www.scopus.com/inward/record.url?eid=2-s2.0-33745060397&partnerID=40&md5=40af588bda1f456f7e819e3daa0b12c2
Keywords: Angiogenesis, Cancer, Integrins, Ischemia, Peptide, Vascular Endothelial Growth Factor, Acetyllysylleucylthreonyltryptophanylglutaminylglutamylleucyltyrosyl Glutaminylleucyllysyltyrosyllysylglycylisoleucinamide, Alanylserylserylseryltyrosylprolylleucylisoleucylhistidyltryptophanyl Arginylprolyltryptophanylalanylarginine, Alanylthreonyltryptophanylleucylprolylprolylarginine, Angiogenesis Inhibitor, Angiogenesis Modulator, Antibody, Arginylarginyllysylarginylarginylarginine, Arginylthreonylglutamylleucylasparaginylvalylglycylisoleucylaspartyl Phenylalanylasparaginyltryptophanylglutamyltyrosylproline, Asparaginylglycyltyrosylglutamylisoleucylglutamyltryptophanyltyrosylseryl Tryptophanylvalylthreonylhistidylglycylmethionyltyrosine, Becaplermin, Bevacizumab, Cysteinylthreonylthreonylhistidyltryptophanylglycylphenylalanylthreonyl Leucylcysteine, Fibroblast Growth Factor 2, Glutaminyllysylarginyllysylarginyllysyllysylserylarginyltyrosyllysylserine, Glycylaspartylglycyltyrosine, Histidylthreonylmethionyltyrosyltyrosylhistidylhistidyltyrosylglutaminyl Histidylhistidylleucine, Monoclonal Antibody Lm 609, Platelet Derived Growth Factor, Pr 39, Receptor Blocking Agent, Seryltyrosylglycylarginyllysyllysylarginylarginylglutaminylarginylarginyl Arginylprolylglutamine, Serylvalylglutaminylmethionyllysylleucine(dibenzofuran) Isoleucylisoleucylvalyllysylleucylasparaginylaspartic Acid, Tryptophanylhistidylserylaspartylmethionylglutamyltryptophanyltryptophanyl Tyrosylleucylleucylglycine, Unclassified Drug, Unindexed Drug, Valylglutamylprolylasparaginylcysteinylaspartylisoleucylhistidylvalyl Methionyltryptophanylglutamyltryptophanylglutamylcysteinylphenylalanylglutamyl Arginylleucinamide, Vasculotropin, Vasculotropin Receptor, Vitronectin Receptor, Vitronectin Receptor Antagonist, Amino Acid Sequence, Antineoplastic Activity, Cardiovascular Disease, Cell Migration, Cell Proliferation, Circulation, Clinical Trial, Complex Formation, Coronary Artery, Diabetic Foot, Drug Targeting, Electron Microscopy, Embryo Development, Endothelium Cell, Extracellular Matrix, Human, Metastasis, Molecular Biology, Molecular Dynamics, Nonhuman, Peptide Analysis, Pericyte, Priority Journal, Protein Analysis, Protein Expression, Protein Function, Protein Secretion, Protein Structure, Revascularization, Review, Smooth Muscle Fiber, Unspecified Side Effect, Vascular Tissue, Animals, Drug Design, Neovascularization, Pathologic, Structure-Activity Relationship, Serylvalylglutaminylmethionyllysylleucine (dibenzofuran) Isoleucylisoleucylvalyllysylleucylasparaginylaspartic Acid, Integrins Antagonists, Inhibitors Metabolism , Neoplasms Blood Supply Drug Therapy Pathology , Pathologic Drug Therapy Metabolism Pathology , Vascular Endothelial Growth Factor Antagonists, Vascular Endothelial Growth Factor A Antagonists,
Affiliations:
*** IBB - CNR ***
Institute of Biostructure and Bioimaging, CNR and Department of Biological Sciences, University of Napoli 'Federico II', via Mezzocannone 16, 80134 Napoli, Italy
References:
Carmeliet, P., Angiogenesis in health and disease (2003) Nat Med, 9, pp. 653-66
Hanahan, D., Folkman, J., Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis (1996) Cell, 86, pp. 353-364
Carmeliet, P., Jain, R.K., Angiogenesis in cancer and other diseases (2000) Nature, 407, pp. 249-257
Yancopoulos, G.D., Davis, S., Gale, N.W., Rudge, J.S., Wiegand, S.J., Holash, J., Vascular-specific growth factors and blood vessel formation (2000) Nature, 407, pp. 242-248
Bergers, G., Benjamin, L.E., Tumorigenesis and the angiogenic switch (2003) Nat Rev Cancer, 3, pp. 401-410
Ruoslahti, E., Specialization of tumour vasculature (2002) Nat Rev Cancer, 2, pp. 83-90
Helisch, A., Schaper, W., Angiogenesis and arteriogenesis - Not yet for prescription (2000) Z Kardiol, 89, pp. 239-244
Simons, M., Ware, J.A., Therapeutic angiogenesis in cardiovascular disease (2003) Nat Rev Drug Discov, 2, pp. 863-871
Schaper, W., Ito, W.D., Molecular mechanisms of coronary collateral vessel growth (1996) Circ Res, 79, pp. 911-919
Schultz, A., Lavie, L., Hochberg, I., Beyar, R., Stone, T., Skorecki, K., Lavie, P., Levy, A.P., Interindividual heterogeneity in the hypoxic regulation of VEGF: Significance for the development of the coronary artery collateral circulation (1999) Circulation, 100, pp. 547-552
Isner, J.M., Tissue responses to ischemia: Local and remote responses for preserving perfusion of ischemic muscle (2000) J Clin Invest, 106, pp. 615-619
Featherstone, J., Griffiths, S., From the analyst's couch. Drugs that target angiogenesis (2002) Nat Rev Drug Discov, 1, pp. 413-414
Jain, R.K., Carmeliet, P.F., Vessels of death or life (2001) Sci Am, 285, pp. 38-45
Emanueli, C., Madeddu, P., Changing the logic of therapeutic angiogenesis for ischemic disease (2005) Trends Mol Med, 11, pp. 207-216
Lee, C.G., Link, H., Baluk, P., Homer, R.J., Chapoval, S., Bhandari, V., Kang, M.J., Elias, J.A., Vascular endothelial growth factor (VEGF) induces remodeling and enhances TH2-mediated sensitization and inflammation in the lung (2004) Nat Med, 10, pp. 1095-1103
Tozer, G.M., Kanthou, C., Baguley, B.C., Disrupting tumour blood vessels (2005) Nat Rev Cancer, 5, pp. 423-435
Cristofanilli, M., Charnsangavej, C., Hortobagyi, G.N., Angiogenesis modulation in cancer research: Novel clinical approaches (2002) Nat Rev Drug Discov, 1, pp. 415-426
Bouma-Ter Steege, J.C.A., Mayo, K.H., Griffioen, A.W., Angiostatic proteins and peptides (2001) Crit Rev Eukaryot Gene Expr, 11, pp. 319-334
Oku, N., Asai, T., Watanabe, K., Kuromi, K., Nagatsuka, M., Kurohane, K., Kikkawa, H., Taki, T., Anti-neovascular therapy using novel peptides homing to angiogenic vessels (2002) Oncogene, 21, pp. 2662-2669
Asai, T., Nagatsuka, M., Kuromi, K., Yamakawa, S., Kurohane, K., Ogino, K., Tanaka, M., Oku, N., Suppression of tumor growth by novel peptides homing to tumor-derived new blood vessels (2002) FEBS Lett, 510, pp. 206-210
Mayo, K.H., Dings, R.P., Flader, C., Nesmelova, I., Hargittai, B., Van Der Schaft, D.W., Van Eijk, L.I., Griffioen, A.W., Design of a partial peptide mimetic of anginex with antiangiogenic and anticancer activity (2003) J Biol Chem, 278, pp. 45746-45752
Blaskovich, M.A., Lin, Q., Delarue, F.L., Sun, J., Park, H.S., Coppola, D., Hamilton, A.D., Sebti, S.M., Design of GFB-111, a platelet-derived growth factor binding molecule with antiangiogenic and anticancer activity against human tumors in mice (2000) Nat Biotechnol, 18, pp. 1065-1070
Koivunen, E., Arap, W., Valtanen, H., Rainisalo, A., Medina, O.P., Heikkila, P., Kantor, C., Pasqualini, R., Tumor targeting with a selective gelatinase inhibitor (1999) Nat Biotechnol, 17, pp. 768-774
Li, J., Post, M., Volk, R., Gao, Y., Li, M., Metais, C., Sato, K., Simons, M., PR39, a peptide regulator of angiogenesis (2000) Nat Med, 6, pp. 49-55
Hamada, Y., Nokihara, K., Okazaki, M., Fujitani, W., Matsumoto, T., Matsuo, M., Umakoshi, Y., Matsuura, N., Angiogenic activity of osteopontin-derived peptide SVVYGLR (2003) Biochem Biophys Res Commun, 310, pp. 153-157
Ferrara, N., VEGF: An update on biological and therapeutic aspects (2000) Curr Opin Biotechnol, 11, pp. 617-624
Ferrara, N., Gerber, H.P., Lecouter, J., The biology of VEGF and its receptors (2003) Nat Med, 9, pp. 669-676
Ferrara, N., Davis-Smyth, T., The biology of vascular endothelial growth factor (1997) Endocr Rev, 18, pp. 4-25
Autiero, M., Waltenberger, J., Communi, D., Kranz, A., Moons, L., Lambrechts, D., Kroll, J., Mayr-Beyrle, U., Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1 (2003) Nat Med, 9, pp. 936-943
Brogi, E., Schatteman, G., Wu, T., Kim, E.A., Varticovski, L., Keyt, B., Isner, J.M., Hypoxia-induced paracrine regulation of vascular endothelial growth factor receptor expression (1996) J Clin Invest, 97, pp. 469-476
Abedi, H., Zachary, I., Vascular endothelial growth factor stimulates tyrosine phosphorylation and recruitment to new focal adhesions of focal adhesion kinase and paxillin in endothelial cells (1997) J Biol Chem, 272, pp. 15442-15451
Muller, Y.A., Li, B., Christinger, H.W., Wells, J.A., Cunningham, B.C., De Vos, A.M., Vascular endothelial growth factor: Crystal structure and functional mapping of the kinase domain receptor binding site (1997) Proc Natl Acad Sci U S a, 94, pp. 7192-7197
Muller, Y.A., Christinger, H.W., Keyt, B.A., De Vos, A.M., The crystal structure of vascular endothelial growth factor (VEGF) refined to 1.93 a resolution: Multiple copy flexibility and receptor binding (1997) Structure, 5, pp. 1325-1338
Wiesmann, C., Christinger, H.W., Cochran, A.G., Cunningham, B.C., Fairbrother, W.J., Keenan, C.J., Meng, G., De Vos, A.M., Crystal structure of the complex between VEGF and a receptor-blocking peptide (1998) Biochemistry, 37, pp. 17765-17772
Pan, B., Li, B., Russell, S.J., Tom, J.Y., Cochran, A.G., Fairbrother, W.J., Solution structure of a phage-derived peptide antagonist in complex with vascular endothelial growth factor (2002) J Mol Biol, 316, pp. 769-787
Muller, Y.A., Chen, Y., Christinger, H.W., Li, B., Cunningham, B.C., Lowman, H.B., De Vos, A.M., VEGF and the Fab fragment of a humanized neutralizing antibody: Crystal structure of the complex at 2.4 a resolution and mutational analysis of the interface (1998) Structure, 6, pp. 1153-1167
Wiesmann, C., Fuh, G., Christinger, H.W., Eigenbrot, C., Wells, J.A., De Vos, A.M., Crystal structure at 1.7 a resolution of VEGF in complex with domain 2 of the Flt-1 receptor (1997) Cell, 91, pp. 695-704
Keyt, B.A., Nguyen, H.V., Berleau, L.T., Duarte, C.M., Park, J., Chen, H., Ferrara, N., Identification of vascular endothelial growth factor determinants for binding KDR and FLT-1 receptors. Generation of receptor-selective VEGF variants by site-directed mutagenesis (1996) J Biol Chem, 271, pp. 5638-5646
Ferrara, N., Hillan, K.J., Gerber, H.P., Novotny, W., Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer (2004) Nat Rev Drug Discov, 3, pp. 391-400
Cooke, S.P., Boxer, G.M., Lawrence, L., Pedley, R.B., Spencer, D.I., Begent, R.H., Chester, K.A., A strategy for antitumor vascular therapy by targeting the vascular endothelial growth factor: Receptor complex (2001) Cancer Res, 61, pp. 3653-3659
Lu, D., Shen, J., Vil, M.D., Zhang, H., Jimenez, X., Bohlen, P., Witte, L., Zhu, Z., Tailoring in vitro selection for a picomolar affinity human antibody directed against vascular endothelial growth factor receptor 2 for enhanced neutralizing activity (2003) J Biol Chem, 278, pp. 43496-43507
Prewett, M., Huber, J., Li, Y., Santiago, A., O'Connor, W., King, K., Overholser, J., Hicklin, D.J., Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors (1999) Cancer Res, 59, pp. 5209-5218
Willett, C.G., Boucher, Y., Di Tomaso, E., Duda, D.G., Munn, L.L., Tong, R.T., Chung, D.C., Fischman, A.J., Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer (2004) Nat Med, 10, pp. 145-147
Underiner, T.L., Ruggeri, B., Gingrich, D.E., Development of vascular endothelial growth factor receptor (VEGFR) kinase inhibitors as anti-angiogenic agents in cancer therapy (2004) Curr Med Chem, 11, pp. 731-745
Sun, J., Wang, D.A., Jain, R.K., Carie, A., Paquette, S., Ennis, E., Blaskovich, M.A., Sebti, S.M., Inhibiting angiogenesis and tumorigenesis by a synthetic molecule that blocks binding of both VEGF and PDGF to their receptors (2005) Oncogene, 24, pp. 4701-4709
Sun, J., Blaskovich, M.A., Jain, R.K., Delarue, F., Paris, D., Brem, S., Wotoczek-Obadia, M., Sebti, S.M., Blocking angiogenesis and tumorigenesis with GFA-116, a synthetic molecule that inhibits binding of vascular endothelial growth factor to its receptor (2004) Cancer Res, 64, pp. 3586-3592
Holash, J., Davis, S., Papadopoulos, N., Croll, S.D., Ho, L., Russell, M., Boland, P., Fandl, J.P., VEGF-Trap: A VEGF blocker with potent antitumor effects (2002) Proc Natl Acad Sci U S a, 99, pp. 11393-11398
Kim, E.S., Serur, A., Huang, J., Manley, C.A., McCrudden, K.W., Frischer, J.S., Soffer, S.Z., Yamashiro, D.J., Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma (2002) Proc Natl Acad Sci U S a, 99, pp. 11399-11404
Takei, Y., Kadomatsu, K., Yuzawa, Y., Matsuo, S., Muramatsu, T., A small interfering RNA targeting vascular endothelial growth factor as cancer therapeutics (2004) Cancer Res, 64, pp. 3365-3370
Niethammer, A.G., Xiang, R., Becker, J.C., Wodrich, H., Pertl, U., Karsten, G., Eliceiri, B.P., Reisfeld, R.A., A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth (2002) Nat Med, 8, pp. 1369-1375
Fairbrother, W.J., Christinger, H.W., Cochran, A.G., Fuh, G., Keenan, C.J., Quan, C., Shriver, S.K., Cunningham, B.C., Novel peptides selected to bind vascular endothelial growth factor target the receptor-binding site (1998) Biochemistry, 37, pp. 17754-17764
Binetruy-Tournaire, R., Demangel, C., Malavaud, B., Vassy, R., Rouyre, S., Kraemer, M., Plouet, J., Mazie, J.C., Identification of a peptide blocking vascular endothelial growth factor (VEGF)-mediated angiogenesis (2000) EMBO J, 19, pp. 1525-1533
El-Mousawi, M., Tchistiakova, L., Yurchenko, L., Pietrzynski, G., Moreno, M., Stanimirovic, D., Ahmad, D., Alakhov, V., A vascular endothelial growth factor high affinity receptor 1-specific peptide with antiangiogenic activity identified using a phage display peptide library (2003) J Biol Chem, 278, pp. 46681-46691
Hetian, L., Ping, A., Shumei, S., Xiaoying, L., Luowen, H., Jian, W., Lin, M., Chengchao, S., A novel peptide isolated from a phage display library inhibits tumor growth and metastasis by blocking the binding of vascular endothelial growth factor to its kinase domain receptor (2002) J Biol Chem, 277, pp. 43137-43142
An, P., Lei, H., Zhang, J., Song, S., He, L., Jin, G., Liu, X., Shou, C., Suppression of tumor growth and metastasis by a VEGFR-1 antagonizing peptide identified from a phage display library (2004) Int J Cancer, 111, pp. 165-173
Zilberberg, L., Shinkaruk, S., Lequin, O., Rousseau, B., Hagedorn, M., Costa, F., Caronzolo, D., Bello, L., Structure and inhibitory effects on angiogenesis and tumor development of a new vascular endothelial growth inhibitor (2003) J Biol Chem, 278, pp. 35564-35573
Bae, D.G., Gho, Y.S., Yoon, W.H., Chae, C.B., Arginine-rich anti-vascular endothelial growth factor peptides inhibit tumor growth and metastasis by blocking angiogenesis (2000) J Biol Chem, 275, pp. 13588-13596
Jia, H., Jezequel, S., Lohr, M., Shaikh, S., Davis, D., Soker, S., Selwood, D., Zachary, I., Peptides encoded by exon 6 of VEGF inhibit endothelial cell biological responses and angiogenesis induced by VEGF (2001) Biochem Biophys Res Commun, 283, pp. 164-173
Piossek, C., Schneider-Mergener, J., Schirner, M., Vakalopoulou, E., Germeroth, L., Thierauch, K.H., Vascular endothelial growth factor (VEGF) receptor II-derived peptides inhibit VEGF (1999) J Biol Chem, 274, pp. 5612-5619
Albini, A., Soldi, R., Giunciuglio, D., Giraudo, E., Benelli, R., Primo, L., Noonan, D., Bussolino, F., The angiogenesis induced by HIV-1 tat protein is mediated by the Flk-1/KDR receptor on vascular endothelial cells (1996) Nat Med, 2, pp. 1371-1375
D'Andrea, L.D., Iaccarino, G., Fattorusso, R., Sorriento, D., Carannante, C., Capasso, D., Trimarco, B., Pedone, C., Targeting angiogenesis: Structural characterization and biological properties of a de novo engineered VEGF mimicking peptide (2005) Proc Natl Acad Sci U S a, 102, pp. 14215-14220
Giancotti, F.G., Ruoslahti, E., Integrin signaling (1999) Science, 285, pp. 1028-1032
Van Der Flier, A., Sonnenberg, A., Function and interactions of integrins (2001) Cell Tissue Res, 305, pp. 285-298
Brooks, P.C., Clark, R.A., Cheresh, D.A., Requirement of vascular integrin alpha v beta 3 for angiogenesis (1994) Science, 264, pp. 569-571
Schlaepfer, D.D., Hauck, C.R., Sieg, D.J., Signaling through focal adhesion kinase (1999) Prog Biophys Mol Biol, 71, pp. 435-478
Longhurst, C.M., Jennings, L.K., Integrin-mediated signal transduction (1998) Cell Mol Life Sci, 54, pp. 514-526
Stupack, D.G., Puente, X.S., Boutsaboualoy, S., Storgard, C.M., Cheresh, D.A., Apoptosis of adherent cells by recruitment of caspase-8 to unligated integrins (2001) J Cell Biol, 155, pp. 459-470
Xiong, J.P., Stehle, T., Diefenbach, B., Zhang, R., Dunker, R., Scott, D.L., Joachimiak, A., Arnaout, M.A., Crystal structure of the extracellular segment of integrin alpha Vbeta3 (2001) Science, 294, pp. 339-345
Gottschalk, K.E., Gunther, R., Kessler, H., A three-state mechanism of integrin activation and signal transduction for integrin alpha(v)beta(3) (2002) Chembiochem, 3, pp. 470-473
Pierschbacher, M.D., Ruoslahti, E., Variants of the cell recognition site of fibronectin that retain attachment-promoting activity (1984) Proc Natl Acad Sci U S a, 81, pp. 5985-5988
Ruoslahti, E., Pierschbacher, M.D., New perspectives in cell adhesion: RGD and integrins (1987) Science, 238, pp. 491-497
Albelda, S.M., Buck, C.A., Integrins and other cell adhesion molecules (1990) FASEB J, 4, pp. 2868-2880
Humphries, M.J., The molecular basis and specificity of integrin-ligand interactions (1990) J Cell Sci, 97 (4), pp. 585-592
Hautanen, A., Gailit, J., Mann, D.M., Ruoslahti, E., Effects of modifications of the RGD sequence and its context on recognition by the fibronectin receptor (1989) J Biol Chem, 264, pp. 1437-1442
Miller, W.H., Keenan, R.M., Willette, R.N., Lark, M.W., Identification and in vivo efficacy of small-molecule antagonists of integrin alphavbeta3 (the vitronectin receptor) (2000) Drug Discov Today, 5, pp. 397-408
Marugan, J.J., Manthey, C., Anaclerio, B., Lafrance, L., Lu, T., Markotan, T., Leonard, K.A., Tomczuk, B., Design, synthesis, and biological evaluation of novel potent and selective alphavbeta3/alphavbeta5 integrin dual inhibitors with improved bioavailability. Selection of the molecular core (2005) J Med Chem, 48, pp. 926-934
Goodman, S.L., Holzemann, G., Sulyok, G.A., Kessler, H., Nanomolar small molecule inhibitors for alphav(beta)6, alphav(beta)5, and alphav(beta)3 integrins (2002) J Med Chem, 45, pp. 1045-1051
Haubner, R., Gratias, R., Diefenbach, B., Goodman, S., Joachimiak, A., Kessler, H., Structural and functional aspects of RGD-containing cyclic pentapeptides as highly potent and selective integrin alphaVbeta3 antagonists (1996) J Am Chem Soc, 118, pp. 7461-7472
Mitjans, F., Meyer, T., Fittschen, C., Goodman, S., Jonczyk, A., Marshall, J.F., Reyes, G., Piulats, J., In vivo therapy of malignant melanoma by means of antagonists of alphav integrins (2000) Int J Cancer, 87, pp. 716-723
Dechantsreiter, M.A., Planker, E., Matha, B., Lohof, E., Holzemann, G., Jonczyk, A., Goodman, S.L., Kessler, H., N-Methylated cyclic RGD peptides as highly active and selective alpha(V)beta(3) integrin antagonists (1999) J Med Chem, 42, pp. 3033-3040
Sulyok, G.A., Gibson, C., Goodman, S.L., Holzemann, G., Wiesner, M., Kessler, H., Solid-phase synthesis of a nonpeptide RGD mimetic library: New selective alphavbeta3 integrin antagonists (2001) J Med Chem, 44, pp. 1938-1950
Belvisi, L., Bernardi, A., Checchia, A., Manzoni, L., Potenza, D., Scolastico, C., Castorina, M., Pisano, C., Potent integrin antagonists from a small library of RGD-including cyclic pseudopeptides (2001) Org Lett, 3, pp. 1001-1004
Posey, J.A., Khazaeli, M.B., Delgrosso, A., Saleh, M.N., Lin, C.Y., Huse, W., Lobuglio, A.F., A pilot trial of Vitaxin, a humanized anti-vitronectin receptor (anti alpha v beta 3) antibody in patients with metastatic cancer (2001) Cancer Biother Radiopharm, 16, pp. 125-132
Kessler, H., Peptide conformations: Part 16. Solid-state carbon-13 NMR spectra of cyclotriprolines (1982) Angew Chem Int Ed Engl, 94, pp. 509-520
Aumailley, M., Gurrath, M., Muller, G., Calvete, J., Timpl, R., Kessler, H., Arg-Gly-Asp constrained within cyclic pentapeptides. Strong and selective inhibitors of cell adhesion to vitronectin and laminin fragment P1 (1991) FEBS Lett, 291, pp. 50-54
Pfaff, M., Tangemann, K., Muller, B., Gurrath, M., Muller, G., Kessler, H., Timpl, R., Engel, J., Selective recognition of cyclic RGD peptides of NMR defined conformation by alpha IIb beta 3, alpha V beta 3, and alpha 5 beta 1 integrins (1994) J Biol Chem, 269, pp. 20233-20238
Haubner, R., Schmitt, W., Holzemann, G., Goodman, S., Jonczyk, A., Kessler, H., Cyclic RGD peptides containing beta-turn mimetics (1996) J Am Chem Soc, 118, pp. 7881-7891
Haubner, R., Finsinger, D., Kessler, H., Stereoisomeric peptide libraries and peptidomimetics for designing selective inhibitors of the avb3 integrin for a new cancer therapy (1997) Angew Chem Int Ed Engl, 36, pp. 1374-1389
Kawaguchi, M., Hosotani, R., Ohishi, S., Fujii, N., Tulachan, S.S., Koizumi, M., Toyoda, E., Imamura, M., A novel synthetic Arg-Gly-Asp-containing peptide cyclo(-RGDf = V-) is the potent inhibitor of angiogenesis (2001) Biochem Biophys Res Commun, 288, pp. 711-717
Coleman, P.J., Brashear, K.M., Hunt, C.A., Hoffman, W.F., Hutchinson, J.H., Breslin, M.J., McVean, C.A., Ma, B., Non-peptide alpha(v)beta(3) antagonists. identification of potent RGD mimetics incorporating novel beta-amino acids as aspartic acid replacements (2002) Bioorg Med Chem Lett, 3, pp. 31-34
Kumar, C.C., Malkowski, M., Yin, Z., Tanghetti, E., Yaremko, B., Nechuta, T., Varner, J., Armstrong, L., Inhibition of angiogenesis and tumor growth by SCH221153, a dual alpha(v)beta3 and alpha(v)beta5 integrin receptor antagonist (2001) Cancer Res, 61, pp. 2232-2238
Urbahns, K., Harter, M., Albers, M., Schmidt, D., Stelte-Ludwig, B., Bruggemeier, U., Vaupel, A., Gerdes, C., Biphenyls as potent vitronectin receptor antagonists (2002) Bioorg Med Chem Lett, 12, pp. 205-208
Van Well, R.M., Overkleeft, H.S., Van Der Marel, G.A., Bruss, D., Thibault, G., De Groot, P.G., Van Boom, J.H., Overhand, M., Solid-phase synthesis of cyclic RGD-furanoid sugar amino acid peptides as integrin inhibitors (2003) Bioorg Med Chem Lett, 13, pp. 331-334
Manthey, C., Lee, Y., Wang, A., Crysler, C., Zhao, S., Bone, R.F., Tomczuk, B.E., Characterization of O-guanidines as novel alphaVbeta3 inhibitors (2001) Proc Am Assoc Cancer Res, 42, p. 368
Marugan, J.J., Haslow, K.D., Crysler, C., Design, synthesis, and biochemical evaluation of novel alpha V beta 3 integrin ligands (2004) Bioorg Med Chem Lett, 14, pp. 4553-4555
Eskens, F.A., Dumez, H., Hoekstra, R., Perschl, A., Brindley, C., Bottcher, S., Wynendaele, W., Van Oosterom, A.T., Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins alphavbeta3 and alphavbeta5 in patients with advanced solid tumours (2003) Eur J Cancer, 39, pp. 917-926
Pasqualini, R., Koivunen, E., Ruoslahti, E., Alpha v integrins as receptors for tumor targeting by circulating ligands (1997) Nat Biotechnol, 15, pp. 542-546
Gante, J., Peptidomimetics - Tailored enzyme inhibitors (1994) Angew Chem Int Ed Engl, 33, pp. 1699-1720
Gante, J., Azapeptides (1989) Synthesis, pp. 405-413
Gould, R.J., Polokoff, M.A., Friedman, P.A., Huang, T.F., Holt, J.C., Cook, J.J., Niewiarowski, S., Disintegrins: A family of integrin inhibitory proteins from viper venoms (1990) Proc Soc Exp Biol Med, 195, pp. 168-171
Niewiarowski, S., McLane, M.A., Kloczewiak, M., Stewart, G.J., Disintegrins and other naturally occurring antagonists of platelet fibrinogen receptors (1994) Semin Hematol, 31, pp. 289-300
Gan, Z.R., Gould, R.J., Jacobs, J.W., Friedman, P.A., Polokoff, M.A., Echistatin. a potent platelet aggregation inhibitor from the venom of the viper, Echis carinatus (1988) J Biol Chem, 263, pp. 19827-19832
Marcinkiewicz, C., Rosenthal, L.A., Mosser, D.M., Kunicki, T.J., Niewiarowski, S., Immunological characterization of eristostatin and echistatin binding sites on alpha IIb beta 3 and alpha V beta 3 integrins (1996) Biochem J, 317 (3), pp. 817-825
Zartler, E.R., Shapiro, M.J., Fragonomics: Fragment-based drug discovery (2005) Curr Opin Chem Biol, 9, pp. 366-370
Yamada, K.M., Even-Ram, S., Integrin regulation of growth factor receptors (2002) Nat Cell Biol, 4, pp. E75-E76
Brooks, P.C., Stromblad, S., Sanders, L.C., Von Schalscha, T.L., Aimes, R.T., Stetler-Stevenson, W.G., Quigley, J.P., Cheresh, D.A., Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3 (1996) Cell, 85, pp. 683-693
De, S., Razorenova, O., McCabe, N.P., O'Toole, T., Qin, J., Byzova, T.V., VEGF-integrin interplay controls tumor growth and vascularization (2005) Proc Natl Acad Sci U S a, 102, pp. 7589-7594
Mizukami, Y., Jo, W.S., Duerr, E.M., Gala, M., Li, J., Zhang, X., Zimmer, M.A., Chung, D.C., Induction of interleukin-8 preserves the angiogenic response in HIF-1alpha-deficient colon cancer cells (2005) Nat Med, 11, pp. 992-997
Carmeliet, P., VEGF gene therapy: Stimulating angiogenesis or angiomagenesis (2000) Nat Med, 6, pp. 1102-1103
Weis, S.M., Cheresh, D.A., Pathophysiological consequences of VEGF-induced vascular permeability (2005) Nature, 437, pp. 497-504
Liu, S., Edwards, D.S., 99mTc-labeled small peptides as diagnostic radiopharmaceuticals (1999) Chem Rev, 99, pp. 2235-2268
Li, S., Peck-Radosavljevic, M., Kienast, O., Preitfellner, J., Hamilton, G., Kurtaran, A., Pirich, C., Dudczak, R., Imaging gastrointestinal tumours using vascular endothelial growth factor-165 (VEGF165) receptor scintigraphy (2003) Ann Oncol, 14, pp. 1274-1277
Haubner, R., Wester, H.J., Radiolabeled tracers for imaging of tumor angiogenesis and evaluation of anti-angiogenic therapies (2004) Curr Pharm des, 10, pp. 1439-1455
Miller, J.C., Pien, H.H., Sahani, D., Sorensen, A.G., Thrall, J.H., Imaging angiogenesis: Applications and potential for drug development (2005) J Natl Cancer Inst, 97, pp. 172-187
Yancopoulos, G. D., Davis, S., Gale, N. W., Rudge, J. S., Wiegand, S. J., Holash, J., Vascular-specific growth factors and blood vessel formation (2000) Nature, 407, pp. 242-248
Isner, J. M., Tissue responses to ischemia: Local and remote responses for preserving perfusion of ischemic muscle (2000) J Clin Invest, 106, pp. 615-619
Jain, R. K., Carmeliet, P. F., Vessels of death or life (2001) Sci Am, 285, pp. 38-45
Lee, C. G., Link, H., Baluk, P., Homer, R. J., Chapoval, S., Bhandari, V., Kang, M. J., Elias, J. A., Vascular endothelial growth factor (VEGF) induces remodeling and enhances TH2-mediated sensitization and inflammation in the lung (2004) Nat Med, 10, pp. 1095-1103
Tozer, G. M., Kanthou, C., Baguley, B. C., Disrupting tumour blood vessels (2005) Nat Rev Cancer, 5, pp. 423-435
Mayo, K. H., Dings, R. P., Flader, C., Nesmelova, I., Hargittai, B., Van Der Schaft, D. W., Van Eijk, L. I., Griffioen, A. W., Design of a partial peptide mimetic of anginex with antiangiogenic and anticancer activity (2003) J Biol Chem, 278, pp. 45746-45752
Blaskovich, M. A., Lin, Q., Delarue, F. L., Sun, J., Park, H. S., Coppola, D., Hamilton, A. D., Sebti, S. M., Design of GFB-111, a platelet-derived growth factor binding molecule with antiangiogenic and anticancer activity against human tumors in mice (2000) Nat Biotechnol, 18, pp. 1065-1070
Muller, Y. A., Li, B., Christinger, H. W., Wells, J. A., Cunningham, B. C., De Vos, A. M., Vascular endothelial growth factor: Crystal structure and functional mapping of the kinase domain receptor binding site (1997) Proc Natl Acad Sci U S a, 94, pp. 7192-7197
Muller, Y. A., Christinger, H. W., Keyt, B. A., De Vos, A. M., The crystal structure of vascular endothelial growth factor (VEGF) refined to 1. 93 a resolution: Multiple copy flexibility and receptor binding (1997) Structure, 5, pp. 1325-1338
Muller, Y. A., Chen, Y., Christinger, H. W., Li, B., Cunningham, B. C., Lowman, H. B., De Vos, A. M., VEGF and the Fab fragment of a humanized neutralizing antibody: Crystal structure of the complex at 2. 4 a resolution and mutational analysis of the interface (1998) Structure, 6, pp. 1153-1167
Keyt, B. A., Nguyen, H. V., Berleau, L. T., Duarte, C. M., Park, J., Chen, H., Ferrara, N., Identification of vascular endothelial growth factor determinants for binding KDR and FLT-1 receptors. Generation of receptor-selective VEGF variants by site-directed mutagenesis (1996) J Biol Chem, 271, pp. 5638-5646
Cooke, S. P., Boxer, G. M., Lawrence, L., Pedley, R. B., Spencer, D. I., Begent, R. H., Chester, K. A., A strategy for antitumor vascular therapy by targeting the vascular endothelial growth factor: Receptor complex (2001) Cancer Res, 61, pp. 3653-3659
Willett, C. G., Boucher, Y., Di Tomaso, E., Duda, D. G., Munn, L. L., Tong, R. T., Chung, D. C., Fischman, A. J., Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer (2004) Nat Med, 10, pp. 145-147
Underiner, T. L., Ruggeri, B., Gingrich, D. E., Development of vascular endothelial growth factor receptor (VEGFR) kinase inhibitors as anti-angiogenic agents in cancer therapy (2004) Curr Med Chem, 11, pp. 731-745
Sun, J., Wang, D. A., Jain, R. K., Carie, A., Paquette, S., Ennis, E., Blaskovich, M. A., Sebti, S. M., Inhibiting angiogenesis and tumorigenesis by a synthetic molecule that blocks binding of both VEGF and PDGF to their receptors (2005) Oncogene, 24, pp. 4701-4709
Kim, E. S., Serur, A., Huang, J., Manley, C. A., McCrudden, K. W., Frischer, J. S., Soffer, S. Z., Yamashiro, D. J., Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma (2002) Proc Natl Acad Sci U S a, 99, pp. 11399-11404
Niethammer, A. G., Xiang, R., Becker, J. C., Wodrich, H., Pertl, U., Karsten, G., Eliceiri, B. P., Reisfeld, R. A., A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth (2002) Nat Med, 8, pp. 1369-1375
Bae, D. G., Gho, Y. S., Yoon, W. H., Chae, C. B., Arginine-rich anti-vascular endothelial growth factor peptides inhibit tumor growth and metastasis by blocking angiogenesis (2000) J Biol Chem, 275, pp. 13588-13596
D'Andrea, L. D., Iaccarino, G., Fattorusso, R., Sorriento, D., Carannante, C., Capasso, D., Trimarco, B., Pedone, C., Targeting angiogenesis: Structural characterization and biological properties of a de novo engineered VEGF mimicking peptide (2005) Proc Natl Acad Sci U S a, 102, pp. 14215-14220
Giancotti, F. G., Ruoslahti, E., Integrin signaling (1999) Science, 285, pp. 1028-1032
Brooks, P. C., Clark, R. A., Cheresh, D. A., Requirement of vascular integrin alpha v beta 3 for angiogenesis (1994) Science, 264, pp. 569-571
Schlaepfer, D. D., Hauck, C. R., Sieg, D. J., Signaling through focal adhesion kinase (1999) Prog Biophys Mol Biol, 71, pp. 435-478
Longhurst, C. M., Jennings, L. K., Integrin-mediated signal transduction (1998) Cell Mol Life Sci, 54, pp. 514-526
Stupack, D. G., Puente, X. S., Boutsaboualoy, S., Storgard, C. M., Cheresh, D. A., Apoptosis of adherent cells by recruitment of caspase-8 to unligated integrins (2001) J Cell Biol, 155, pp. 459-470
Xiong, J. P., Stehle, T., Diefenbach, B., Zhang, R., Dunker, R., Scott, D. L., Joachimiak, A., Arnaout, M. A., Crystal structure of the extracellular segment of integrin alpha Vbeta3 (2001) Science, 294, pp. 339-345
Gottschalk, K. E., Gunther, R., Kessler, H., A three-state mechanism of integrin activation and signal transduction for integrin alpha (v) beta (3) (2002) Chembiochem, 3, pp. 470-473
Pierschbacher, M. D., Ruoslahti, E., Variants of the cell recognition site of fibronectin that retain attachment-promoting activity (1984) Proc Natl Acad Sci U S a, 81, pp. 5985-5988
Albelda, S. M., Buck, C. A., Integrins and other cell adhesion molecules (1990) FASEB J, 4, pp. 2868-2880
Humphries, M. J., The molecular basis and specificity of integrin-ligand interactions (1990) J Cell Sci, 97 (4), pp. 585-592
Miller, W. H., Keenan, R. M., Willette, R. N., Lark, M. W., Identification and in vivo efficacy of small-molecule antagonists of integrin alphavbeta3 (the vitronectin receptor) (2000) Drug Discov Today, 5, pp. 397-408
Marugan, J. J., Manthey, C., Anaclerio, B., Lafrance, L., Lu, T., Markotan, T., Leonard, K. A., Tomczuk, B., Design, synthesis, and biological evaluation of novel potent and selective alphavbeta3/alphavbeta5 integrin dual inhibitors with improved bioavailability. Selection of the molecular core (2005) J Med Chem, 48, pp. 926-934
Goodman, S. L., Holzemann, G., Sulyok, G. A., Kessler, H., Nanomolar small molecule inhibitors for alphav (beta) 6, alphav (beta) 5, and alphav (beta) 3 integrins (2002) J Med Chem, 45, pp. 1045-1051
Dechantsreiter, M. A., Planker, E., Matha, B., Lohof, E., Holzemann, G., Jonczyk, A., Goodman, S. L., Kessler, H., N-Methylated cyclic RGD peptides as highly active and selective alpha (V) beta (3) integrin antagonists (1999) J Med Chem, 42, pp. 3033-3040
Sulyok, G. A., Gibson, C., Goodman, S. L., Holzemann, G., Wiesner, M., Kessler, H., Solid-phase synthesis of a nonpeptide RGD mimetic library: New selective alphavbeta3 integrin antagonists (2001) J Med Chem, 44, pp. 1938-1950
Posey, J. A., Khazaeli, M. B., Delgrosso, A., Saleh, M. N., Lin, C. Y., Huse, W., Lobuglio, A. F., A pilot trial of Vitaxin, a humanized anti-vitronectin receptor (anti alpha v beta 3) antibody in patients with metastatic cancer (2001) Cancer Biother Radiopharm, 16, pp. 125-132
Coleman, P. J., Brashear, K. M., Hunt, C. A., Hoffman, W. F., Hutchinson, J. H., Breslin, M. J., McVean, C. A., Ma, B., Non-peptide alpha (v) beta (3) antagonists. identification of potent RGD mimetics incorporating novel beta-amino acids as aspartic acid replacements (2002) Bioorg Med Chem Lett, 3, pp. 31-34
Kumar, C. C., Malkowski, M., Yin, Z., Tanghetti, E., Yaremko, B., Nechuta, T., Varner, J., Armstrong, L., Inhibition of angiogenesis and tumor growth by SCH221153, a dual alpha (v) beta3 and alpha (v) beta5 integrin receptor antagonist (2001) Cancer Res, 61, pp. 2232-2238
Van Well, R. M., Overkleeft, H. S., Van Der Marel, G. A., Bruss, D., Thibault, G., De Groot, P. G., Van Boom, J. H., Overhand, M., Solid-phase synthesis of cyclic RGD-furanoid sugar amino acid peptides as integrin inhibitors (2003) Bioorg Med Chem Lett, 13, pp. 331-334
Marugan, J. J., Haslow, K. D., Crysler, C., Design, synthesis, and biochemical evaluation of novel alpha V beta 3 integrin ligands (2004) Bioorg Med Chem Lett, 14, pp. 4553-4555
Eskens, F. A., Dumez, H., Hoekstra, R., Perschl, A., Brindley, C., Bottcher, S., Wynendaele, W., Van Oosterom, A. T., Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins alphavbeta3 and alphavbeta5 in patients with advanced solid tumours (2003) Eur J Cancer, 39, pp. 917-926
Gould, R. J., Polokoff, M. A., Friedman, P. A., Huang, T. F., Holt, J. C., Cook, J. J., Niewiarowski, S., Disintegrins: A family of integrin inhibitory proteins from viper venoms (1990) Proc Soc Exp Biol Med, 195, pp. 168-171
Gan, Z. R., Gould, R. J., Jacobs, J. W., Friedman, P. A., Polokoff, M. A., Echistatin. a potent platelet aggregation inhibitor from the venom of the viper, Echis carinatus (1988) J Biol Chem, 263, pp. 19827-19832
Zartler, E. R., Shapiro, M. J., Fragonomics: Fragment-based drug discovery (2005) Curr Opin Chem Biol, 9, pp. 366-370
Yamada, K. M., Even-Ram, S., Integrin regulation of growth factor receptors (2002) Nat Cell Biol, 4, pp. E75-E76
Brooks, P. C., Stromblad, S., Sanders, L. C., Von Schalscha, T. L., Aimes, R. T., Stetler-Stevenson, W. G., Quigley, J. P., Cheresh, D. A., Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3 (1996) Cell, 85, pp. 683-693
Weis, S. M., Cheresh, D. A., Pathophysiological consequences of VEGF-induced vascular permeability (2005) Nature, 437, pp. 497-504
Miller, J. C., Pien, H. H., Sahani, D., Sorensen, A. G., Thrall, J. H., Imaging angiogenesis: Applications and potential for drug development (2005) J Natl Cancer Inst, 97, pp. 172-187
Peptide-based molecules in angiogenesis
Angiogenesis refers to the process of remodeling the vascular tissue characterized by the branching out of a new blood vessel from a pre-existing vessel. Angiogenesis is particularly active during embryogenesis, while during adult life it is quiescent and limited to particular physiologic phenomena. Recently, the study of molecular mechanisms of angiogenesis has stirred renewed interest due to the recognition of the role played by angiogenesis in several pathologies of significant medical impact, such as cancer and cardiovascular disease, and due to the pharmacologic interest rising from the possibility of modulating these phenomena. Antibodies, peptides and small molecules targeting active endothelial cells represent an innovative tool in therapeutic and diagnostic fields. In this study, we reviewed the literature of peptide and peptidomimetics in angiogenesis and their potential applications. Two specific protein systems, namely the vascular endothelial growth factor and its receptor and integrins, will be discussed in detail. © 2006 Blackwell Munksgaard.
Angiogenesis refers to the process of remodeling the vascular tissue characterized by the branching out of a new blood vessel from a pre-existing vessel. Angiogenesis is particularly active during embryogenesis, while during adult life it is quiescent and limited to particular physiologic phenomena. Recently, the study of molecular mechanisms of angiogenesis has stirred renewed interest due to the recognition of the role played by angiogenesis in several pathologies of significant medical impact, such as cancer and cardiovascular disease, and due to the pharmacologic interest rising from the possibility of modulating these phenomena. Antibodies, peptides and small molecules targeting active endothelial cells represent an innovative tool in therapeutic and diagnostic fields. In this study, we reviewed the literature of peptide and peptidomimetics in angiogenesis and their potential applications. Two specific protein systems, namely the vascular endothelial growth factor and its receptor and integrins, will be discussed in detail. © 2006 Blackwell Munksgaard.
Peptide-based molecules in angiogenesis
Peptide-based molecules in angiogenesis
Other filter: ([btitle,keywords] "Angiogenesis" OR [bt ...
Miro C, Nappi A, Cicatiello AG, Di Cicco E, Sagliocchi S, Murolo M, Belli V, Troiani T, Albanese S, Amiranda S, Zavacki AM, Stornaiuolo M, Mancini M, Salvatore D, Dentice M
* Thyroid Hormone Enhances Angiogenesis and the Warburg Effect in Squamous Cell Carcinomas (12 views)
Cancers (ISSN: 2072-6694linking), 2021 Jun 1; 13(11): N/D-N/D.
Impact Factor: 6.126
View Export to BibTeX Export to EndNote
Capasso D, Del Gatto A, Comegna D, Russo L, Fattorusso R, Saviano M, Di Gaetano S, Zaccaro L
* Selective Targeting of αvβ5 Integrin in HepG2 Cell Line by RGDechi15D Peptide (108 views)
Molecules (ISSN: 1420-3049linking, 1420-3049electronic), 2020 Sep 19; 25(18): N/D-N/D.
Impact Factor: 3.267
View Export to BibTeX Export to EndNote
Nawaz MI, Rezzola S, Tobia C, Coltrini D, Belleri M, Mitola S, Corsini M, Sandomenico A, Caporale A, Ruvo M, Presta M
* D-Peptide analogues of Boc-Phe-Leu-Phe-Leu-Phe-COOH induce neovascularization via endothelial N-formyl peptide receptor (71 views)
Angiogenesis (ISSN: 0969-6970linking), 2020 Aug; 23(3): 357-369.
Impact Factor: 9.78
View Export to BibTeX Export to EndNote
Tarallo V, Iaccarino E, Cicatiello V, Sanna R, Ruvo M, De Falco S
* Oral Delivery of a Tetrameric Tripeptide Inhibitor of VEGFR1 Suppresses Pathological Choroid Neovascularization (195 views)
Int J Mol Sc (ISSN: 1422-0067linking, 1661-6596, 1422-0067electronic), 2020 Jan 9; 21 (2 ): N/D-N/D.
Impact Factor: 2.598
View Export to BibTeX Export to EndNote
Di Stasi R, Diana D, De Rosa L, Fattorusso R, D'Andrea LD
* Biochemical and Conformational Characterization of Recombinant VEGFR2 Domain "7" (226 views)
Mol Biotechnol (ISSN: 1073-6085linking, 1559-0305electronic), 2019 Nov; 61(11): 860-872.
Impact Factor: 2.275
View Export to BibTeX Export to EndNote
Cimmino I, Margheri F, Prisco F, Perruolo G, D'Esposito V, Laurenzana A, Fibbi G, Paciello O, Doti N, Ruvo M, Miele C, Beguinot F, Formisano P, Oriente F
* Prep1 regulates angiogenesis through a PGC-1alpha-mediated mechanism (219 views)
Faseb J (ISSN: 0892-6638linking), 2019 Oct 15; 33(12): 13893-13904.
Impact Factor: 5.391
View Export to BibTeX Export to EndNote
Conte C, Moret F, Esposito D, Dal Poggetto G, Avitabile C, Ungaro F, Romanelli A, Laurienzo P, Reddi E, Quaglia F
* Biodegradable nanoparticles exposing a short anti-FLT1 peptide as antiangiogenic platform to complement docetaxel anticancer activity (215 views)
Mater Sci Eng C Mater Biol Appl (ISSN: 0928-4931linking), 2019 Sep; 102: 876-886.
Impact Factor: 5.08
View Export to BibTeX Export to EndNote
Wang L, Coric P, Broussy S, Di Stasi R, Zhou L, D'Andrea LD, Ji L, Vidal M, Bouaziz S, Liu WQ
* Structural studies of the binding of an antagonistic cyclic peptide to the VEGFR1 domain "2" (224 views)
Eur J Med Chem (ISSN: 0223-5234linking, 1768-3254, 1768-3254electronic), 2019 May 1; 169: 65-75.
Impact Factor: 2.882
View Export to BibTeX Export to EndNote
Di Stasi R, De Rosa L, Diana D, Fattorusso R, D'Andrea LD
* Human Recombinant VEGFR2D4 Biochemical Characterization to Investigate Novel Anti-VEGFR2D4 Antibodies for Allosteric Targeting of VEGFR2 (287 views)
Mol Biotechnol (ISSN: 1073-6085linking, 1559-0305electronic), 2019 Apr 26; 61(7): 513-520.
Impact Factor: 2.275
View Export to BibTeX Export to EndNote
De Simone G
* Targeted treatment of anaerobic cancer. Patent evaluation of US2016279084 and US2017056350 (225 views)
Expert Opin Ther Pat (ISSN: 1744-7674electronic, 1354-3776linking), 2019 Jan; 29(1): 1-6.
Impact Factor: 3.699
View Export to BibTeX Export to EndNote
De Rosa L, Di Stasi R, D'Andrea LD
* Pro-angiogenic peptides in biomedicine (481 views)
Arch Bioch Bioph (ISSN: 0003-9861, 0003-9861linking), 2018; 660: 72-86.
Impact Factor: 3.118
View Export to BibTeX Export to EndNote
Di Stasi R, Diana D, Capasso D, Di Gaetano S, De Rosa L, Celentano V, Isernia C, Fattorusso R, D'Andrea LD
* VEGFR Recognition Interface of a Proangiogenic VEGF-Mimetic Peptide Determined In Vitro and in the Presence of Endothelial Cells by NMR Spectroscopy (338 views)
Chemistry (ISSN: 0947-6539, 1521-3765, 1521-3765electronic), 2018; 24(44): 11461-11466.
Impact Factor: 5.16
View Export to BibTeX Export to EndNote
Petrillo S, Chiabrando D, Genova T, Fiorito V, Ingoglia G, Vinchi F, Mussano F, Carossa S, Silengo L, Altruda F, Merlo GR, Munaron L, Tolosano E
* Heme accumulation in endothelial cells impairs angiogenesis by triggering paraptosis (201 views)
Cell Death Differ (ISSN: 1350-9047, 1476-5403electronic), 2017 Dec 11; N/D: N/D-N/D.
Impact Factor: 8
View Export to BibTeX Export to EndNote
Crich SG, Terreno E, Aime S
* Nano-sized and other improved reporters for magnetic resonance imaging of angiogenesis (253 views)
Adv Drug Deliver Rev (ISSN: 0169-409x), 2017 Sep 15; 119: 61-72.
Impact Factor: 13.66
View Export to BibTeX Export to EndNote
Consolino L, Longo DL, Sciortino M, Dastru W, Cabodi S, Giovenzana GB, Aime S
* Assessing tumor vascularization as a potential biomarker of imatinib resistance in gastrointestinal stromal tumors by dynamic contrast-enhanced magnetic resonance imaging (263 views)
Gastric Cancer (ISSN: 1436-3291, 1436-3291linking), 2016 Dec 19; 20(4): 629-639.
Impact Factor: 5.454
View Export to BibTeX Export to EndNote
La Mendola D, Arnesano F, Hansson O, Giacomelli C, Calo V, Mangini V, Magrì A, Bellia F, Trincavelli ML, Martini C, Natile G, Rizzarelli E
* Copper binding to naturally occurring, lactam form of angiogenin differs from that to recombinant protein, affecting their activity (407 views)
Metallomics (ISSN: 1756-5901, 1756-591x), 2016 Jan 20; 8(1): 118-124.
Impact Factor: 3.975
View Export to BibTeX Export to EndNote
Consolino L, Longo DL, Dastrù W, Cutrin JC, Dettori D, Lanzardo S, Oliviero S, Cavallo F, Aime S
* Functional imaging of the angiogenic switch in a transgenic mouse model of human breast cancer by dynamic contrast enhanced magnetic resonance imaging (308 views)
Int J Cancer (ISSN: 0020-7136), 2016; N/D: N/D-N/D.
Impact Factor: 6.513
View Export to BibTeX Export to EndNote
Bogdanovich S, Kim Y, Mizutani T, Yasuma R, Tudisco L, Cicatiello V, Bastos-carvalho A, Kerur N, Hirano Y, Baffi JZ, Tarallo V, Li S, Yasuma T, Arpitha P, Fowler BJ, Wright CB, Apicella I, Greco A, Brunetti A, Ruvo M, Sandomenico A, Nozaki M, Ijima R, Kaneko H, Ogura Y, Terasaki H, Ambati BK, Leusen JH, Langdon WY, Clark MR, Armour KL, Bruhns P, Verbeek JS, Gelfand BD, De Falco S, Ambati J
* Human IgG1 antibodies suppress angiogenesis in a target-independent manner (557 views)
Signal Transduct Target Ther (ISSN: 2059-3635print), 2016; 1: N/D-N/D.
Impact Factor: 0
View Export to BibTeX Export to EndNote
Di Stasi R, De Rosa L, Romanelli A, D'Andrea LD
* Peptides Interacting with Growth Factor Receptors Regulating Angiogenesis (350 views)
Frontiers In Medicinal Chemistry, 2016; 9: 103-160.
Impact Factor: 0
View Export to BibTeX Export to EndNote
Grasso G, Santoro AM, Magrì A, La Mendola D, Tomasello MF, Zimbone S, Rizzarelli E
* The Inorganic Perspective of VEGF: Interactions of Cu2 + with Peptides Encompassing a Recognition Domain of the VEGF Receptor (434 views)
J Chem Res (ISSN: 0162-0134, 1873-3344, 0162-0134print), 2016; 159: 149-158.
Impact Factor: 3.348
View Export to BibTeX Export to EndNote
Pignataro G, Ziaco B, Tortiglione A, Gala R, Cuomo O, Vinciguerra A, Lapi D, Mastantuono T, Anzilotti S, D'Andrea LD, Pedone C, Di Renzo G, Annunziato L, Cataldi M
* Neuroprotective Effect of VEGF-Mimetic Peptide QK in Experimental Brain Ischemia Induced in Rat by Middle Cerebral Artery Occlusion (286 views)
Acs Chem Neurosci (ISSN: 1948-7193, 1948-7193electronic), 2015 Sep 16; 6(9): 1517-1525.
Impact Factor: 4.348
View Export to BibTeX Export to EndNote
Giacomelli C, Trincavelli ML, Satriano C, Hansson O, La Mendola D, Rizzarelli E, Martini C
* Copper (II) ions modulate Angiogenin activity in human endothelial cells (424 views)
Int J Biochem Cell B (ISSN: 1357-2725), 2015 Mar; 60: 185-196.
Impact Factor: 3.905
View Export to BibTeX Export to EndNote
Ciccarelli M, Rusciano MR, Sorriento D, Maione AS, Soprano M, Iaccarino G, Illario M
* Messages from the Border: Novel Insights in Signal Transduction Pathways Involved in Tumor Invasion and Metastasis (237 views)
Journal Of Cancer Therapy (ISSN: 2151-1934), 2015 Feb 11; 6: 199-212.
Impact Factor: 0.56
View Export to BibTeX Export to EndNote
Diana D, Russomanno A, De Rosa L, Di Stasi R, Capasso D, Di Gaetano S, Romanelli A, Russo L, D'Andrea LD, Fattorusso R
* Functional Binding Surface Of A Beta-Hairpin Vegf Receptor Targeting Peptide Determined By Nmr Spectroscopy In Living Cells (445 views)
Chemistry (ISSN: 0947-6539, 1521-3765, 1521-3765electronic), 2015 Jan 2; 21(1): 91-95.
Impact Factor: 5.771
View Export to BibTeX Export to EndNote
Longo DL, Dastrù W, Consolino L, Espak M, Arigoni M, Cavallo F, Aime S
* Cluster analysis of quantitative parametric maps from DCE-MRI: Application in evaluating heterogeneity of tumor response to antiangiogenic treatment (488 views)
Magn Reson Imaging (ISSN: 0730-725x), 2015; 33(6): 725-736.
Impact Factor: 1.98
View Export to BibTeX Export to EndNote
Cicatiello V, Apicella I, Tudisco L, Tarallo V, Formisano L, Sandomenico A, Kim Y, Bastos-Carvalho A, Orlandi A, Ambati J, Ruvo M, Bianco R, de Falco S
* Powerful anti-tumor and anti-angiogenic activity of a new anti-vascular endothelial growth factor receptor 1 peptide in colorectal cancer models (470 views)
Oncotarget (ISSN: 1949-2553, 1949-2553electronic, 1949-2553linking), 2015; 6(12): 10563-10576.
Impact Factor: 5.008
View Export to BibTeX Export to EndNote
Carriero MV, Bifulco K, Minopoli M, Lista L, Maglio O, Mele L, Di Carluccio G, De Rosa M, Pavone V
* UPARANT: a urokinase receptor-derived peptide inhibitor of VEGF-driven angiogenesis with enhanced stability and in vitro and in vivo potency (467 views)
Mol Cancer Ther (ISSN: 1535-7163, 1538-8514electronic), 2014 May; 13(5): 1092-1104.
Impact Factor: 5.683
View Export to BibTeX Export to EndNote
Nold-Petry CA, Rudloff I, Baumer Y, Ruvo M, Marasco D, Botti P, Farkas L, Cho SX, Zepp JA, Azam T, Dinkel H, Palmer BE, Boisvert WA, Cool CD, Taraseviciene-Stewart L, Heinhuis B, Joosten LA, Dinarello CA, Voelkel NF, Nold MF
* IL-32 Promotes Angiogenesis (846 views)
J Immunol (ISSN: 0022-1767), 2014 Jan 15; 192(2): 589-602.
Impact Factor: 4.922
View Export to BibTeX Export to EndNote
De Rosa L, Diana D, Basile A, Russomanno A, Isernia C, Turco MC, Fattorusso R, D'Andrea LD
* Design, Structural And Biological Characterization Of A Vegf Inhibitor Beta-Hairpin-Constrained Peptide (510 views)
Eur J Med Chem (ISSN: 0223-5234, 1768-3254, 0223-5234linking), 2014; 73: 210-216.
Impact Factor: 3.447
View Export to BibTeX Export to EndNote
Mancini M, Greco A, Salvatore G, Liuzzi R, Di Maro G, Vergara E, Chiappetta G, Pasquinelli R, Brunetti A, Salvatore M
* Imaging of thyroid tumor angiogenesis with microbubbles targeted to vascular endothelial growth factor receptor type 2 in mice (485 views)
Bmc Med Imaging (ISSN: 1471-2342, 1471-2342electronic), 2013 Sep 12; 13(1): 31-31.
Impact Factor: 0.983
View Export to BibTeX Export to EndNote
Diana D, Di Stasi R, De Rosa L, Isernia C, D'Andrea LD, Fattorusso R
* Structural investigation of the VEGF receptor interaction with a helical antagonist peptide (415 views)
J Pept Sci (ISSN: 1075-2617, 1099-1387, 1075-2617print), 2013 Apr; 19(4): 214-219.
Impact Factor: 1.862
View Export to BibTeX Export to EndNote
Pisano M, De Paola I, Nieddu V, Sassu I, Cossu S, Galleri G, Del Gatto A, Budroni M, Cossu A, Saviano M, Palmieri G, Zaccaro L, Rozzo C
* In vitro activity of the alphavbeta3 integrin antagonist RGDechi-hCit on malignant melanoma cells (447 views)
Anticancer Res (ISSN: 0250-7005, 0250-0700, 1791-7530electronic), 2013 Mar; 33(3): 871-879.
Impact Factor: 1.045
View Export to BibTeX Export to EndNote
Galasso G, De Rosa R, Ciccarelli M, Sorriento D, Del Giudice C, Strisciuglio T, De Biase C, Luciano R, Piccolo R, Pierri A, Di Gioia G, Prevete N, Trimarco B, Piscione F, Iaccarino G
* β2-adrenergic receptor stimulation improves endothelial progenitor cell-mediated ischemic neoangiogenesis (473 views)
Circ Res (ISSN: 0009-7330, 1524-4571electronic, 0009-7330linking), 2013; 112(7): 1026-1034.
Impact Factor: 11.089
View Export to BibTeX Export to EndNote
Finetti F, Basile A, Capasso D, Di Gaetano S, Di Stasi R, Pascale M, Turco CM, Ziche M, Morbidelli L, D'Andrea LD
* Functional and pharmacological characterization of a VEGF mimetic peptide on reparative angiogenesis (607 views)
Biochem Pharmacol Biochemical Pharmacology (ISSN: 0006-2952, 1873-2968), 2012 Sep 1; 84(3): 303-311.
Impact Factor: 4.576
View Export to BibTeX Export to EndNote
Magrì A, D'Alessandro F, Di Stefano DA, Campagna T, Pappalardo G, Impellizzeri G, La Mendola D
* Copper(ii) Coordination Properties Of The Integrin Ligand Sequence Phsrn And Its New Beta-Cyclodextrin Conjugates (497 views)
Journal Of Inorganic Biochemistry, 2012 Sep; 113: 15-24.
Impact Factor: 3.444
View Export to BibTeX Export to EndNote
Ziaco B, Diana D, Capasso D, Palumbo R, Celentano V, Di Stasi R, Fattorusso R, D'Andrea LD
* C-terminal truncation of Vascular Endothelial Growth Factor mimetic helical peptide preserves structural and receptor binding properties (370 views)
Biochem Biophys Res Commun (ISSN: 0006-291x), 2012 Jul 27; 424(2): 290-294.
Impact Factor: 2.406
View Export to BibTeX Export to EndNote
La Mendola D, Magrì A, Santoro AM, Nicoletti VG, Rizzarelli E
* Copper(II) interaction with peptide fragments of histidine-proline-rich glycoprotein: Speciation, stability and binding details (409 views)
J Chem Res (ISSN: 1873-3344, 0162-0134, 0162-0134print), 2012 Jun; 111: 59-69.
Impact Factor: 3.197
View Export to BibTeX Export to EndNote
Santulli G, Cipolletta E, Sorriento D, Del Giudice C, Anastasio A, Monaco S, Maione AS, Condorelli G, Puca A, Trimarco B, Illario M, Iaccarino G
* CaMK4 gene deletion induces hypertension (349 views)
J Am Heart Assoc Journal Of The American Heart Association (ISSN: 2047-9980), 2012; 1(4): N/D-N/D.
Impact Factor: 2.882
View Export to BibTeX Export to EndNote
Sorriento D, Santulli G, Del Giudice C, Anastasio A, Trimarco B, Iaccarino G
* Endothelial cells are able to synthesize and release catecholamines both in vitro and in vivo (424 views)
Hypertensionhypertension (ISSN: 0194-911x), 2012; 60(1): 129-136.
Impact Factor: 6.873
View Export to BibTeX Export to EndNote
Diana D, Basile A, De Rosa L, Di Stasi R, Auriemma S, Arra C, Pedone C, Turco MC, Fattorusso R, D'Andrea LD
* Beta-Hairpin Peptide That Targets Vascular Endothelial Growth Factor (vegf) Receptors: Design, Nmr Characterization, And Biological Activity (620 views)
Jbc Papers (ISSN: 1083-351x, 0021-9258, 0021-9258linking), 2011 Dec 2; 286(48): 41680-41691.
Impact Factor: 4.773
View Export to BibTeX Export to EndNote
Ruvo M, Sandomenico A, Tudisco L, De Falco S
* Branched peptides for the modulation of protein-protein interactions: More arms are better than one? (532 views)
Curr Med Chem (ISSN: 0929-8673, 1875-533x, 1875-533xelectronic), 2011 Jun; 18(16): 2429-2437.
Impact Factor: 4.859
View Export to BibTeX Export to EndNote
Perrone-filardi P, Dellegrottaglie S, Rudd JH, Costanzo P, Marciano C, Vassallo E, Marsico F, Ruggiero D, Petretta MP, Chiariello M, Cuocolo A
* Molecular imaging of atherosclerosis in translational medicine (756 views)
Eur J Nucl Med (ISSN: 1619-7089, 1619-7070, 0340-6997), 2011 May; 38(5): 969-975.
Impact Factor: 4.991
View Export to BibTeX Export to EndNote
Basile A, Del Gatto A, Diana D, Di Stasi R, Falco A, Festa M, Rosati A, Barbieri A, Franco R, Arra C, Pedone C, Fattorusso R, Turco MC, D'Andrea LD
* Characterization of a designed vascular endothelial growth factor receptor antagonist helical peptide with antiangiogenic activity in vivo (558 views)
J Med Chem (ISSN: 1520-4804, 0022-2623, 0022-2623print), 2011 Mar 10; 54(5): 1391-1400.
Impact Factor: 5.248
View Export to BibTeX Export to EndNote
Santulli G, Basilicata MF, De Simone M, Del Giudice C, Anastasio A, Sorriento D, Saviano M, Del Gatto A, Trimarco B, Pedone C, Zaccaro L, Iaccarino G
* Evaluation of the anti-angiogenic properties of the new selective alphaVbeta3 integrin antagonist RGDechiHCit (511 views)
J Transl Med (ISSN: 1479-5876electronic), 2011 Jan 13; 9: 7-7.
Impact Factor: 3.474
View Export to BibTeX Export to EndNote
Ciccarelli M, Sorriento D, Cipolletta E, Santulli G, Fusco A, Zhou R-H, Eckhart AD, Peppel K, Koch WJ, Trimarco B, Iaccarino G
* Impaired neoangiogenesis in β2-adrenoceptor gene-deficient mice: Restoration by intravascular human β2-adrenoceptor gene transfer and role of NFkB and CREB transcription factors (370 views)
Br J Pharmacol British Journal Of Pharmacology (ISSN: 0007-1188), 2011; 162(3): 712-721.
Impact Factor: 4.409
View Export to BibTeX Export to EndNote
Dettin M, Ghezzo F, Conconi MT, Urbani L, D'Auria G, Falcigno L, Guidolin D, Nico B, Ribatti D, Di Bello C, Parnigotto PP
* In vitro and in vivo pro-angiogenic effects of thymosin-β4-derived peptides (482 views)
Cell Immunol (ISSN: 0008-8749), 2011; 271(2): 299-307.
Impact Factor: 1.974
View Export to BibTeX Export to EndNote
La Mendola D, Magrì A, Vagliasindi LI, Hansson Ö, Bonomo RP, Rizzarelli E
* Copper(II) complex formation with a linear peptide encompassing the putative cell binding site of angiogenin (449 views)
Dalton T (ISSN: 1477-9234, 1477-9226, 1477-9234electronic), 2010 Nov 28; 39(44): 10678-10684.
Impact Factor: 3.647
View Export to BibTeX Export to EndNote
D'Andrea LD, Romanelli A, Di Stasi R, Pedone C
* Bioinorganic aspects of angiogenesis (543 views)
Dalton T (ISSN: 1477-9234, 1477-9226, 1477-9234electronic), 2010 Sep 7; 39(33): 7625-7636.
Impact Factor: 3.647
View Export to BibTeX Export to EndNote
Del Vecchio S, Zannetti A, Fonti R, Iommelli F, Pizzuti LM, Lettieri A, Salvatore M
* PET/CT in cancer research: From preclinical to clinical applications (636 views)
Contrast Media Mol Imaging (ISSN: 1555-4309, 1555-4309linking), 2010 Jul; 5(4): 190-200.
Impact Factor: 4.02
View Export to BibTeX Export to EndNote
Gautier B, Goncalves V, Diana D, Di Stasi R, Teillet F, Lenoir C, Huguenot F, Garbay C, Fattorusso R, D'Andrea LD, Vidal M, Inguimbert N
* Biochemical and Structural Analysis of the Binding Determinants of a Vascular Endothelial Growth Factor Receptor Peptidic Antagonist (573 views)
J Med Chem (ISSN: 0022-2623, 1520-4804, 0022-2623print), 2010 Jun 10; 53(11): 4428-4440.
Impact Factor: 5.207
View Export to BibTeX Export to EndNote
Del Vecchio S, Zannetti A, Iommelli F, Lettieri A, Brunetti A, Salvatore M
* Molecular imaging of tumor microenvironment (504 views)
Q J Nucl Med Mol Im (ISSN: 1824-4785, 1824-4478, 1824-4785linking), 2010 Jun; 54(3): 243-258.
Impact Factor: 1.724
View Export to BibTeX Export to EndNote
Del Vecchio S, Zannetti A, Iommelli F, Lettieri A, Brunetti A, Salvatore M
* Molecular imaging of tumor microenvironment: Challenges and perspectives (597 views)
Q J Nucl Med Mol Im (ISSN: 1824-4785, 1824-4478, 1824-4785linking), 2010 Jun; 54(3): 249-258.
Impact Factor: 1.724
View Export to BibTeX Export to EndNote
Diana D, Ziaco B, Scarabelli G, Pedone C, Colombo G, D'Andrea LD, Fattorusso R
* Structural analysis of a helical peptide unfolding pathway (507 views)
Chemistry (ISSN: 1521-3765, 0947-6539, 1521-3765electronic), 2010 May 10; 16(18): 5400-5407.
Impact Factor: 5.476
View Export to BibTeX Export to EndNote
Di Stasi R, Diana D, Capasso D, Palumbo R, Romanelli A, Pedone C, Fattorusso R, D'Andrea LD
* VEGFR1(D2) in drug discovery: Expression and molecular characterization (352 views)
Biopolymers (ISSN: 0006-3525, 0006-6352, 0006-3525print), 2010; 94(6): 800-809.
Impact Factor: 2.572
View Export to BibTeX Export to EndNote
D'Andrea LD, Del Gatto A, De Rosa L, Romanelli A, Pedone C
* Peptides targeting angiogenesis related growth factor receptors (14589 views)
Curr Pharm Des Current Pharmaceutical Design (ISSN: 1873-4286, 1381-6128), 2009 Jul; 15(21): 2414-2429.
Impact Factor: 4.414
View Export to BibTeX Export to EndNote
Santulli G, Ciccarelli M, Palumbo G, Campanile A, Galasso G, Ziaco B, Altobelli GG, Cimini V, Piscione F, D'Andrea LD, Pedone C, Trimarco B, Iaccarino G
* In vivo properties of the proangiogenic peptide QK (417 views)
J Transl Med (ISSN: 1479-5876, 1479-5876electronic, 1479-5876linking), 2009 Jun 8; 7: 41-41.
Impact Factor: 3.407
View Export to BibTeX Export to EndNote
Cho WG, Albuquerque RJ, Kleinman ME, Tarallo V, Greco A, Nozaki M, Green MG, Baffi JZ, Ambati BK, De Falco M, Alexander JS, Brunetti A, De Falco S, Ambati J
* Small interfering RNA-induced TLR3 activation inhibits blood and lymphatic vessel growth (421 views)
P Natl Acad Sci Usa (ISSN: 0027-8424, 1091-6490, 0027-8424print), 2009 Apr 28; 106(17): 7137-7142.
Impact Factor: 9.432
View Export to BibTeX Export to EndNote
Cittadini A, Monti MG, Castiello MC, D'Arco E, Galasso G, Sorriento D, Saldamarco L, De Paulis A, Napoli R, Iaccarino G, Saccà L
* Insulin-like growth factor-1 protects from vascular stenosis and accelerates re-endothelialization in a rat model of carotid artery injury (466 views)
J Thromb Haemost Journal Of Thrombosis And Haemostasis (ISSN: 1538-7933), 2009; 7(11): 1920-1928.
Impact Factor: 6.069
View Export to BibTeX Export to EndNote
Ponticelli S, Marasco D, Tarallo V, Albuquerque RJC, Mitola S, Takeda A, Stassen J, Presta M, Ambati J, Ruvo M, De Falco S
* Modulation of Angiogenesis by a Tetrameric Tripeptide That Antagonizes Vascular Endothelial Growth Factor Receptor (615 views)
Jbc Papers (ISSN: 0021-9258, 1083-351x, 0021-9258linking), 2008 Dec 5; 283(49): 34250-34259.
Impact Factor: 5.52
View Export to BibTeX Export to EndNote
Dudar GK, D'Andrea LD, Di Stasi R, Pedone C, Wallace JL
* A vascular endothelial growth factor mimetic accelerates gastric ulcer healing in an iNOS-dependent manner (923 views)
Am J Physiol Gastrointest Liver Physiol American Journal Of Physiology Gastrointestinal And Liver Physiology (ISSN: 0193-1857), 2008 Sep; 295(2): G374-G381.
Impact Factor: 3.587
View Export to BibTeX Export to EndNote
Ponticelli S, Takeda A, Mitola S, Stassen J, Presta M, Ambati J, Ruvo M, De Falco S, Marasco D
* Angiogenesis modulation: identification of tetrameric tripeptide as inhibitor of VEGFR-1 by the screening of peptide combinatiorial libraries (351 views)
J Pept Sci (ISSN: 1075-2617, 1099-1387, 1075-2617print), 2008 Sep; 14(8): N/D-N/D.
Impact Factor: 1.654
View Export to BibTeX Export to EndNote
Di Stasi R, Capasso D, Diana D, Fattorusso R, Pedone C, D'Andrea LD
* Vascular Endothelial Growth Factor (VEGF) and its receptors: key regulators of angiogenesis (290 views)
J Pept Sci (ISSN: 1075-2617, 1099-1387, 1075-2617print), 2008 Sep; 14(8): N/D-N/D.
Impact Factor: 1.654
View Export to BibTeX Export to EndNote
Leese MP, Jourdan FL, Gaukroger K, Mahon MF, Newman SP, Foster PA, Stengel C, Regis-Lydi S, Ferrandis E, Di Fiore A, De Simone G, Supuran CT, Purohit A, Reed MJ, Potter BVL
* Structure-activity relationships of C-17 cyano-substituted estratrienes as anticancer agents (464 views)
J Med Chem (ISSN: 0022-2623, 1520-4804, 0022-2623print), 2008 Mar 13; 51(5): 1295-1308.
Impact Factor: 4.898
View Export to BibTeX Export to EndNote
Diana D, Ziaco B, Colombo G, Scarabelli G, Romanelli A, Fedone C, Fattorusso R, D'Andrea LD
* Structural determinants of the unusual helix stability of a de novo engineered vascular endothelial growth factor (VEGF) mimicking peptide (470 views)
Chemistry (ISSN: 0947-6539, 1521-3765, 1521-3765electronic), 2008; 14(14): 4164-4166.
Impact Factor: 5.454
View Export to BibTeX Export to EndNote
Sorriento D, Ciccarelli M, Santulli G, Campanile A, Altobelli GG, Cimini V, Galasso G, Astone D, Piscione F, Pastore L, Trimarco B, Iaccarino G
* The G-protein-coupled receptor kinase 5 inhibits NFκB transcriptional activity by inducing nuclear accumulation of IκBα (438 views)
P Natl Acad Sci Usa (ISSN: 0027-8424, 1091-6490, 0027-8424print), 2008; 105(46): 17818-17823.
Impact Factor: 9.38
View Export to BibTeX Export to EndNote
Costantino V, De Rosa C, Fattorusso E, Imperatore C, Mangoni A, Irace C, Maffettone C, Capasso D, Malorni L, Palumbo R, Pedone C
* Oreacerebrosides: Bioactive cerebrosides with a triunsaturated sphingoid base from the sea star Oreaster reticulatus (262 views)
Eur J Org Chem (ISSN: 1434-193x), 2007 Nov; (31): 5277-5283.
Impact Factor: 2.914
View Export to BibTeX Export to EndNote
Zannetti A, Fonti R, Iommelli F, Papaccioli A, Sommella J, Tortora G, Bianco R, Salvatore M, Del Vecchio S
* SPECT imaging of endoplasmic reticulum-mediated tumor response to gefitinib and erlotinib in lung cancer (424 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2007 Oct; 34: 277-309.
Impact Factor: 4.101
View Export to BibTeX Export to EndNote
Ntziachristos V, Cuénod CA, Fournier L, Balvay D, Pradel C, Siauve N, Clement O, Jouannot E, Lucidarme O, Vecchio SD, Salvatore M, Law B, Tung C-H, Jain RK, Fukumura D, Munn LL, Brown EB, Schellenberger E, Montet X, Weissleder R, Clerck ND, Postnov A
* Tumor Imaging (350 views)
Textbook Of In Vivo Imaging In Vertebrates (ISSN: 9780-4700), 2007 Jul 16; 1: 277-309.
Impact Factor: 1.148
View Export to BibTeX Export to EndNote
Del Gatto A, Zaccaro L, Grieco P, Novellino E, Zannetti A, Del Vecchio S, Iommelli F, Salvatore M, Pedone C, Saviano M
* Novel And Selective Alpha (v) Beta3 Receptor Peptide Antagonist: Design, Synthesis, And Biological Behavior (730 views)
J Med Chem (ISSN: 0022-2623, 1520-4804, 0022-2623print), 2006 Jun 1; 49(11): 3416-3420.
Impact Factor: 5.115
View Export to BibTeX Export to EndNote
Del Gatto A, D'Andrea LD, Zaccaro L, Saviano M, Pedone C, Benedetti E
* Engineering Peptides In Angiogenesis (418 views)
Biopolymers, 2006; 0: 215-216.
Impact Factor: 2.288
View Export to BibTeX Export to EndNote
D'Andrea LD, Iaccarino G, Fattorusso R, Sorriento D, Carannante C, Capasso D, Trimarco B, Pedone C
* Targeting angiogenesis: Structural characterization and biological properties of a de novo engineered VEGF mimicking peptide (657 views)
P Natl Acad Sci Usa (ISSN: 0027-8424, 1091-6490, 0027-8424print), 2005 Oct 4; 102(40): 14215-14220.
Impact Factor: 10.231
View Export to BibTeX Export to EndNote
Iaccarino G, Ciccarelli M, Sorriento D, Galasso G, Campanile A, Santulli G, Cipolletta E, Cerullo V, Cimini V, Altobelli GG, Piscione F, Priante O, Pastore L, Chiariello M, Salvatore F, Koch WJ, Trimarco B
* Ischemic neoangiogenesis enhanced by β2-adrenergic receptor overexpression: A novel role for the endothelial adrenergic system (380 views)
Circ Res (ISSN: 0009-7330, 1524-4571electronic), 2005; 97(11): 1182-1189.
Impact Factor: 9.408
View Export to BibTeX Export to EndNote
Salvatore M, Fonti R
* New frontiers of nuclear medicine (457 views)
Tumori (ISSN: 0300-8916, 0300-8916print, 0300-8916linking), 2002 May; 88(3): S60-S60.
Impact Factor: 0.267
View Export to BibTeX Export to EndNote
* Thyroid Hormone Enhances Angiogenesis and the Warburg Effect in Squamous Cell Carcinomas (12 views)
Cancers (ISSN: 2072-6694linking), 2021 Jun 1; 13(11): N/D-N/D.
Impact Factor: 6.126
View Export to BibTeX Export to EndNote
Capasso D, Del Gatto A, Comegna D, Russo L, Fattorusso R, Saviano M, Di Gaetano S, Zaccaro L
* Selective Targeting of αvβ5 Integrin in HepG2 Cell Line by RGDechi15D Peptide (108 views)
Molecules (ISSN: 1420-3049linking, 1420-3049electronic), 2020 Sep 19; 25(18): N/D-N/D.
Impact Factor: 3.267
View Export to BibTeX Export to EndNote
Nawaz MI, Rezzola S, Tobia C, Coltrini D, Belleri M, Mitola S, Corsini M, Sandomenico A, Caporale A, Ruvo M, Presta M
* D-Peptide analogues of Boc-Phe-Leu-Phe-Leu-Phe-COOH induce neovascularization via endothelial N-formyl peptide receptor (71 views)
Angiogenesis (ISSN: 0969-6970linking), 2020 Aug; 23(3): 357-369.
Impact Factor: 9.78
View Export to BibTeX Export to EndNote
Tarallo V, Iaccarino E, Cicatiello V, Sanna R, Ruvo M, De Falco S
* Oral Delivery of a Tetrameric Tripeptide Inhibitor of VEGFR1 Suppresses Pathological Choroid Neovascularization (195 views)
Int J Mol Sc (ISSN: 1422-0067linking, 1661-6596, 1422-0067electronic), 2020 Jan 9; 21 (2 ): N/D-N/D.
Impact Factor: 2.598
View Export to BibTeX Export to EndNote
Di Stasi R, Diana D, De Rosa L, Fattorusso R, D'Andrea LD
* Biochemical and Conformational Characterization of Recombinant VEGFR2 Domain "7" (226 views)
Mol Biotechnol (ISSN: 1073-6085linking, 1559-0305electronic), 2019 Nov; 61(11): 860-872.
Impact Factor: 2.275
View Export to BibTeX Export to EndNote
Cimmino I, Margheri F, Prisco F, Perruolo G, D'Esposito V, Laurenzana A, Fibbi G, Paciello O, Doti N, Ruvo M, Miele C, Beguinot F, Formisano P, Oriente F
* Prep1 regulates angiogenesis through a PGC-1alpha-mediated mechanism (219 views)
Faseb J (ISSN: 0892-6638linking), 2019 Oct 15; 33(12): 13893-13904.
Impact Factor: 5.391
View Export to BibTeX Export to EndNote
Conte C, Moret F, Esposito D, Dal Poggetto G, Avitabile C, Ungaro F, Romanelli A, Laurienzo P, Reddi E, Quaglia F
* Biodegradable nanoparticles exposing a short anti-FLT1 peptide as antiangiogenic platform to complement docetaxel anticancer activity (215 views)
Mater Sci Eng C Mater Biol Appl (ISSN: 0928-4931linking), 2019 Sep; 102: 876-886.
Impact Factor: 5.08
View Export to BibTeX Export to EndNote
Wang L, Coric P, Broussy S, Di Stasi R, Zhou L, D'Andrea LD, Ji L, Vidal M, Bouaziz S, Liu WQ
* Structural studies of the binding of an antagonistic cyclic peptide to the VEGFR1 domain "2" (224 views)
Eur J Med Chem (ISSN: 0223-5234linking, 1768-3254, 1768-3254electronic), 2019 May 1; 169: 65-75.
Impact Factor: 2.882
View Export to BibTeX Export to EndNote
Di Stasi R, De Rosa L, Diana D, Fattorusso R, D'Andrea LD
* Human Recombinant VEGFR2D4 Biochemical Characterization to Investigate Novel Anti-VEGFR2D4 Antibodies for Allosteric Targeting of VEGFR2 (287 views)
Mol Biotechnol (ISSN: 1073-6085linking, 1559-0305electronic), 2019 Apr 26; 61(7): 513-520.
Impact Factor: 2.275
View Export to BibTeX Export to EndNote
De Simone G
* Targeted treatment of anaerobic cancer. Patent evaluation of US2016279084 and US2017056350 (225 views)
Expert Opin Ther Pat (ISSN: 1744-7674electronic, 1354-3776linking), 2019 Jan; 29(1): 1-6.
Impact Factor: 3.699
View Export to BibTeX Export to EndNote
De Rosa L, Di Stasi R, D'Andrea LD
* Pro-angiogenic peptides in biomedicine (481 views)
Arch Bioch Bioph (ISSN: 0003-9861, 0003-9861linking), 2018; 660: 72-86.
Impact Factor: 3.118
View Export to BibTeX Export to EndNote
Di Stasi R, Diana D, Capasso D, Di Gaetano S, De Rosa L, Celentano V, Isernia C, Fattorusso R, D'Andrea LD
* VEGFR Recognition Interface of a Proangiogenic VEGF-Mimetic Peptide Determined In Vitro and in the Presence of Endothelial Cells by NMR Spectroscopy (338 views)
Chemistry (ISSN: 0947-6539, 1521-3765, 1521-3765electronic), 2018; 24(44): 11461-11466.
Impact Factor: 5.16
View Export to BibTeX Export to EndNote
Petrillo S, Chiabrando D, Genova T, Fiorito V, Ingoglia G, Vinchi F, Mussano F, Carossa S, Silengo L, Altruda F, Merlo GR, Munaron L, Tolosano E
* Heme accumulation in endothelial cells impairs angiogenesis by triggering paraptosis (201 views)
Cell Death Differ (ISSN: 1350-9047, 1476-5403electronic), 2017 Dec 11; N/D: N/D-N/D.
Impact Factor: 8
View Export to BibTeX Export to EndNote
Crich SG, Terreno E, Aime S
* Nano-sized and other improved reporters for magnetic resonance imaging of angiogenesis (253 views)
Adv Drug Deliver Rev (ISSN: 0169-409x), 2017 Sep 15; 119: 61-72.
Impact Factor: 13.66
View Export to BibTeX Export to EndNote
Consolino L, Longo DL, Sciortino M, Dastru W, Cabodi S, Giovenzana GB, Aime S
* Assessing tumor vascularization as a potential biomarker of imatinib resistance in gastrointestinal stromal tumors by dynamic contrast-enhanced magnetic resonance imaging (263 views)
Gastric Cancer (ISSN: 1436-3291, 1436-3291linking), 2016 Dec 19; 20(4): 629-639.
Impact Factor: 5.454
View Export to BibTeX Export to EndNote
La Mendola D, Arnesano F, Hansson O, Giacomelli C, Calo V, Mangini V, Magrì A, Bellia F, Trincavelli ML, Martini C, Natile G, Rizzarelli E
* Copper binding to naturally occurring, lactam form of angiogenin differs from that to recombinant protein, affecting their activity (407 views)
Metallomics (ISSN: 1756-5901, 1756-591x), 2016 Jan 20; 8(1): 118-124.
Impact Factor: 3.975
View Export to BibTeX Export to EndNote
Consolino L, Longo DL, Dastrù W, Cutrin JC, Dettori D, Lanzardo S, Oliviero S, Cavallo F, Aime S
* Functional imaging of the angiogenic switch in a transgenic mouse model of human breast cancer by dynamic contrast enhanced magnetic resonance imaging (308 views)
Int J Cancer (ISSN: 0020-7136), 2016; N/D: N/D-N/D.
Impact Factor: 6.513
View Export to BibTeX Export to EndNote
Bogdanovich S, Kim Y, Mizutani T, Yasuma R, Tudisco L, Cicatiello V, Bastos-carvalho A, Kerur N, Hirano Y, Baffi JZ, Tarallo V, Li S, Yasuma T, Arpitha P, Fowler BJ, Wright CB, Apicella I, Greco A, Brunetti A, Ruvo M, Sandomenico A, Nozaki M, Ijima R, Kaneko H, Ogura Y, Terasaki H, Ambati BK, Leusen JH, Langdon WY, Clark MR, Armour KL, Bruhns P, Verbeek JS, Gelfand BD, De Falco S, Ambati J
* Human IgG1 antibodies suppress angiogenesis in a target-independent manner (557 views)
Signal Transduct Target Ther (ISSN: 2059-3635print), 2016; 1: N/D-N/D.
Impact Factor: 0
View Export to BibTeX Export to EndNote
Di Stasi R, De Rosa L, Romanelli A, D'Andrea LD
* Peptides Interacting with Growth Factor Receptors Regulating Angiogenesis (350 views)
Frontiers In Medicinal Chemistry, 2016; 9: 103-160.
Impact Factor: 0
View Export to BibTeX Export to EndNote
Grasso G, Santoro AM, Magrì A, La Mendola D, Tomasello MF, Zimbone S, Rizzarelli E
* The Inorganic Perspective of VEGF: Interactions of Cu2 + with Peptides Encompassing a Recognition Domain of the VEGF Receptor (434 views)
J Chem Res (ISSN: 0162-0134, 1873-3344, 0162-0134print), 2016; 159: 149-158.
Impact Factor: 3.348
View Export to BibTeX Export to EndNote
Pignataro G, Ziaco B, Tortiglione A, Gala R, Cuomo O, Vinciguerra A, Lapi D, Mastantuono T, Anzilotti S, D'Andrea LD, Pedone C, Di Renzo G, Annunziato L, Cataldi M
* Neuroprotective Effect of VEGF-Mimetic Peptide QK in Experimental Brain Ischemia Induced in Rat by Middle Cerebral Artery Occlusion (286 views)
Acs Chem Neurosci (ISSN: 1948-7193, 1948-7193electronic), 2015 Sep 16; 6(9): 1517-1525.
Impact Factor: 4.348
View Export to BibTeX Export to EndNote
Giacomelli C, Trincavelli ML, Satriano C, Hansson O, La Mendola D, Rizzarelli E, Martini C
* Copper (II) ions modulate Angiogenin activity in human endothelial cells (424 views)
Int J Biochem Cell B (ISSN: 1357-2725), 2015 Mar; 60: 185-196.
Impact Factor: 3.905
View Export to BibTeX Export to EndNote
Ciccarelli M, Rusciano MR, Sorriento D, Maione AS, Soprano M, Iaccarino G, Illario M
* Messages from the Border: Novel Insights in Signal Transduction Pathways Involved in Tumor Invasion and Metastasis (237 views)
Journal Of Cancer Therapy (ISSN: 2151-1934), 2015 Feb 11; 6: 199-212.
Impact Factor: 0.56
View Export to BibTeX Export to EndNote
Diana D, Russomanno A, De Rosa L, Di Stasi R, Capasso D, Di Gaetano S, Romanelli A, Russo L, D'Andrea LD, Fattorusso R
* Functional Binding Surface Of A Beta-Hairpin Vegf Receptor Targeting Peptide Determined By Nmr Spectroscopy In Living Cells (445 views)
Chemistry (ISSN: 0947-6539, 1521-3765, 1521-3765electronic), 2015 Jan 2; 21(1): 91-95.
Impact Factor: 5.771
View Export to BibTeX Export to EndNote
Longo DL, Dastrù W, Consolino L, Espak M, Arigoni M, Cavallo F, Aime S
* Cluster analysis of quantitative parametric maps from DCE-MRI: Application in evaluating heterogeneity of tumor response to antiangiogenic treatment (488 views)
Magn Reson Imaging (ISSN: 0730-725x), 2015; 33(6): 725-736.
Impact Factor: 1.98
View Export to BibTeX Export to EndNote
Cicatiello V, Apicella I, Tudisco L, Tarallo V, Formisano L, Sandomenico A, Kim Y, Bastos-Carvalho A, Orlandi A, Ambati J, Ruvo M, Bianco R, de Falco S
* Powerful anti-tumor and anti-angiogenic activity of a new anti-vascular endothelial growth factor receptor 1 peptide in colorectal cancer models (470 views)
Oncotarget (ISSN: 1949-2553, 1949-2553electronic, 1949-2553linking), 2015; 6(12): 10563-10576.
Impact Factor: 5.008
View Export to BibTeX Export to EndNote
Carriero MV, Bifulco K, Minopoli M, Lista L, Maglio O, Mele L, Di Carluccio G, De Rosa M, Pavone V
* UPARANT: a urokinase receptor-derived peptide inhibitor of VEGF-driven angiogenesis with enhanced stability and in vitro and in vivo potency (467 views)
Mol Cancer Ther (ISSN: 1535-7163, 1538-8514electronic), 2014 May; 13(5): 1092-1104.
Impact Factor: 5.683
View Export to BibTeX Export to EndNote
Nold-Petry CA, Rudloff I, Baumer Y, Ruvo M, Marasco D, Botti P, Farkas L, Cho SX, Zepp JA, Azam T, Dinkel H, Palmer BE, Boisvert WA, Cool CD, Taraseviciene-Stewart L, Heinhuis B, Joosten LA, Dinarello CA, Voelkel NF, Nold MF
* IL-32 Promotes Angiogenesis (846 views)
J Immunol (ISSN: 0022-1767), 2014 Jan 15; 192(2): 589-602.
Impact Factor: 4.922
View Export to BibTeX Export to EndNote
De Rosa L, Diana D, Basile A, Russomanno A, Isernia C, Turco MC, Fattorusso R, D'Andrea LD
* Design, Structural And Biological Characterization Of A Vegf Inhibitor Beta-Hairpin-Constrained Peptide (510 views)
Eur J Med Chem (ISSN: 0223-5234, 1768-3254, 0223-5234linking), 2014; 73: 210-216.
Impact Factor: 3.447
View Export to BibTeX Export to EndNote
Mancini M, Greco A, Salvatore G, Liuzzi R, Di Maro G, Vergara E, Chiappetta G, Pasquinelli R, Brunetti A, Salvatore M
* Imaging of thyroid tumor angiogenesis with microbubbles targeted to vascular endothelial growth factor receptor type 2 in mice (485 views)
Bmc Med Imaging (ISSN: 1471-2342, 1471-2342electronic), 2013 Sep 12; 13(1): 31-31.
Impact Factor: 0.983
View Export to BibTeX Export to EndNote
Diana D, Di Stasi R, De Rosa L, Isernia C, D'Andrea LD, Fattorusso R
* Structural investigation of the VEGF receptor interaction with a helical antagonist peptide (415 views)
J Pept Sci (ISSN: 1075-2617, 1099-1387, 1075-2617print), 2013 Apr; 19(4): 214-219.
Impact Factor: 1.862
View Export to BibTeX Export to EndNote
Pisano M, De Paola I, Nieddu V, Sassu I, Cossu S, Galleri G, Del Gatto A, Budroni M, Cossu A, Saviano M, Palmieri G, Zaccaro L, Rozzo C
* In vitro activity of the alphavbeta3 integrin antagonist RGDechi-hCit on malignant melanoma cells (447 views)
Anticancer Res (ISSN: 0250-7005, 0250-0700, 1791-7530electronic), 2013 Mar; 33(3): 871-879.
Impact Factor: 1.045
View Export to BibTeX Export to EndNote
Galasso G, De Rosa R, Ciccarelli M, Sorriento D, Del Giudice C, Strisciuglio T, De Biase C, Luciano R, Piccolo R, Pierri A, Di Gioia G, Prevete N, Trimarco B, Piscione F, Iaccarino G
* β2-adrenergic receptor stimulation improves endothelial progenitor cell-mediated ischemic neoangiogenesis (473 views)
Circ Res (ISSN: 0009-7330, 1524-4571electronic, 0009-7330linking), 2013; 112(7): 1026-1034.
Impact Factor: 11.089
View Export to BibTeX Export to EndNote
Finetti F, Basile A, Capasso D, Di Gaetano S, Di Stasi R, Pascale M, Turco CM, Ziche M, Morbidelli L, D'Andrea LD
* Functional and pharmacological characterization of a VEGF mimetic peptide on reparative angiogenesis (607 views)
Biochem Pharmacol Biochemical Pharmacology (ISSN: 0006-2952, 1873-2968), 2012 Sep 1; 84(3): 303-311.
Impact Factor: 4.576
View Export to BibTeX Export to EndNote
Magrì A, D'Alessandro F, Di Stefano DA, Campagna T, Pappalardo G, Impellizzeri G, La Mendola D
* Copper(ii) Coordination Properties Of The Integrin Ligand Sequence Phsrn And Its New Beta-Cyclodextrin Conjugates (497 views)
Journal Of Inorganic Biochemistry, 2012 Sep; 113: 15-24.
Impact Factor: 3.444
View Export to BibTeX Export to EndNote
Ziaco B, Diana D, Capasso D, Palumbo R, Celentano V, Di Stasi R, Fattorusso R, D'Andrea LD
* C-terminal truncation of Vascular Endothelial Growth Factor mimetic helical peptide preserves structural and receptor binding properties (370 views)
Biochem Biophys Res Commun (ISSN: 0006-291x), 2012 Jul 27; 424(2): 290-294.
Impact Factor: 2.406
View Export to BibTeX Export to EndNote
La Mendola D, Magrì A, Santoro AM, Nicoletti VG, Rizzarelli E
* Copper(II) interaction with peptide fragments of histidine-proline-rich glycoprotein: Speciation, stability and binding details (409 views)
J Chem Res (ISSN: 1873-3344, 0162-0134, 0162-0134print), 2012 Jun; 111: 59-69.
Impact Factor: 3.197
View Export to BibTeX Export to EndNote
Santulli G, Cipolletta E, Sorriento D, Del Giudice C, Anastasio A, Monaco S, Maione AS, Condorelli G, Puca A, Trimarco B, Illario M, Iaccarino G
* CaMK4 gene deletion induces hypertension (349 views)
J Am Heart Assoc Journal Of The American Heart Association (ISSN: 2047-9980), 2012; 1(4): N/D-N/D.
Impact Factor: 2.882
View Export to BibTeX Export to EndNote
Sorriento D, Santulli G, Del Giudice C, Anastasio A, Trimarco B, Iaccarino G
* Endothelial cells are able to synthesize and release catecholamines both in vitro and in vivo (424 views)
Hypertensionhypertension (ISSN: 0194-911x), 2012; 60(1): 129-136.
Impact Factor: 6.873
View Export to BibTeX Export to EndNote
Diana D, Basile A, De Rosa L, Di Stasi R, Auriemma S, Arra C, Pedone C, Turco MC, Fattorusso R, D'Andrea LD
* Beta-Hairpin Peptide That Targets Vascular Endothelial Growth Factor (vegf) Receptors: Design, Nmr Characterization, And Biological Activity (620 views)
Jbc Papers (ISSN: 1083-351x, 0021-9258, 0021-9258linking), 2011 Dec 2; 286(48): 41680-41691.
Impact Factor: 4.773
View Export to BibTeX Export to EndNote
Ruvo M, Sandomenico A, Tudisco L, De Falco S
* Branched peptides for the modulation of protein-protein interactions: More arms are better than one? (532 views)
Curr Med Chem (ISSN: 0929-8673, 1875-533x, 1875-533xelectronic), 2011 Jun; 18(16): 2429-2437.
Impact Factor: 4.859
View Export to BibTeX Export to EndNote
Perrone-filardi P, Dellegrottaglie S, Rudd JH, Costanzo P, Marciano C, Vassallo E, Marsico F, Ruggiero D, Petretta MP, Chiariello M, Cuocolo A
* Molecular imaging of atherosclerosis in translational medicine (756 views)
Eur J Nucl Med (ISSN: 1619-7089, 1619-7070, 0340-6997), 2011 May; 38(5): 969-975.
Impact Factor: 4.991
View Export to BibTeX Export to EndNote
Basile A, Del Gatto A, Diana D, Di Stasi R, Falco A, Festa M, Rosati A, Barbieri A, Franco R, Arra C, Pedone C, Fattorusso R, Turco MC, D'Andrea LD
* Characterization of a designed vascular endothelial growth factor receptor antagonist helical peptide with antiangiogenic activity in vivo (558 views)
J Med Chem (ISSN: 1520-4804, 0022-2623, 0022-2623print), 2011 Mar 10; 54(5): 1391-1400.
Impact Factor: 5.248
View Export to BibTeX Export to EndNote
Santulli G, Basilicata MF, De Simone M, Del Giudice C, Anastasio A, Sorriento D, Saviano M, Del Gatto A, Trimarco B, Pedone C, Zaccaro L, Iaccarino G
* Evaluation of the anti-angiogenic properties of the new selective alphaVbeta3 integrin antagonist RGDechiHCit (511 views)
J Transl Med (ISSN: 1479-5876electronic), 2011 Jan 13; 9: 7-7.
Impact Factor: 3.474
View Export to BibTeX Export to EndNote
Ciccarelli M, Sorriento D, Cipolletta E, Santulli G, Fusco A, Zhou R-H, Eckhart AD, Peppel K, Koch WJ, Trimarco B, Iaccarino G
* Impaired neoangiogenesis in β2-adrenoceptor gene-deficient mice: Restoration by intravascular human β2-adrenoceptor gene transfer and role of NFkB and CREB transcription factors (370 views)
Br J Pharmacol British Journal Of Pharmacology (ISSN: 0007-1188), 2011; 162(3): 712-721.
Impact Factor: 4.409
View Export to BibTeX Export to EndNote
Dettin M, Ghezzo F, Conconi MT, Urbani L, D'Auria G, Falcigno L, Guidolin D, Nico B, Ribatti D, Di Bello C, Parnigotto PP
* In vitro and in vivo pro-angiogenic effects of thymosin-β4-derived peptides (482 views)
Cell Immunol (ISSN: 0008-8749), 2011; 271(2): 299-307.
Impact Factor: 1.974
View Export to BibTeX Export to EndNote
La Mendola D, Magrì A, Vagliasindi LI, Hansson Ö, Bonomo RP, Rizzarelli E
* Copper(II) complex formation with a linear peptide encompassing the putative cell binding site of angiogenin (449 views)
Dalton T (ISSN: 1477-9234, 1477-9226, 1477-9234electronic), 2010 Nov 28; 39(44): 10678-10684.
Impact Factor: 3.647
View Export to BibTeX Export to EndNote
D'Andrea LD, Romanelli A, Di Stasi R, Pedone C
* Bioinorganic aspects of angiogenesis (543 views)
Dalton T (ISSN: 1477-9234, 1477-9226, 1477-9234electronic), 2010 Sep 7; 39(33): 7625-7636.
Impact Factor: 3.647
View Export to BibTeX Export to EndNote
Del Vecchio S, Zannetti A, Fonti R, Iommelli F, Pizzuti LM, Lettieri A, Salvatore M
* PET/CT in cancer research: From preclinical to clinical applications (636 views)
Contrast Media Mol Imaging (ISSN: 1555-4309, 1555-4309linking), 2010 Jul; 5(4): 190-200.
Impact Factor: 4.02
View Export to BibTeX Export to EndNote
Gautier B, Goncalves V, Diana D, Di Stasi R, Teillet F, Lenoir C, Huguenot F, Garbay C, Fattorusso R, D'Andrea LD, Vidal M, Inguimbert N
* Biochemical and Structural Analysis of the Binding Determinants of a Vascular Endothelial Growth Factor Receptor Peptidic Antagonist (573 views)
J Med Chem (ISSN: 0022-2623, 1520-4804, 0022-2623print), 2010 Jun 10; 53(11): 4428-4440.
Impact Factor: 5.207
View Export to BibTeX Export to EndNote
Del Vecchio S, Zannetti A, Iommelli F, Lettieri A, Brunetti A, Salvatore M
* Molecular imaging of tumor microenvironment (504 views)
Q J Nucl Med Mol Im (ISSN: 1824-4785, 1824-4478, 1824-4785linking), 2010 Jun; 54(3): 243-258.
Impact Factor: 1.724
View Export to BibTeX Export to EndNote
Del Vecchio S, Zannetti A, Iommelli F, Lettieri A, Brunetti A, Salvatore M
* Molecular imaging of tumor microenvironment: Challenges and perspectives (597 views)
Q J Nucl Med Mol Im (ISSN: 1824-4785, 1824-4478, 1824-4785linking), 2010 Jun; 54(3): 249-258.
Impact Factor: 1.724
View Export to BibTeX Export to EndNote
Diana D, Ziaco B, Scarabelli G, Pedone C, Colombo G, D'Andrea LD, Fattorusso R
* Structural analysis of a helical peptide unfolding pathway (507 views)
Chemistry (ISSN: 1521-3765, 0947-6539, 1521-3765electronic), 2010 May 10; 16(18): 5400-5407.
Impact Factor: 5.476
View Export to BibTeX Export to EndNote
Di Stasi R, Diana D, Capasso D, Palumbo R, Romanelli A, Pedone C, Fattorusso R, D'Andrea LD
* VEGFR1(D2) in drug discovery: Expression and molecular characterization (352 views)
Biopolymers (ISSN: 0006-3525, 0006-6352, 0006-3525print), 2010; 94(6): 800-809.
Impact Factor: 2.572
View Export to BibTeX Export to EndNote
D'Andrea LD, Del Gatto A, De Rosa L, Romanelli A, Pedone C
* Peptides targeting angiogenesis related growth factor receptors (14589 views)
Curr Pharm Des Current Pharmaceutical Design (ISSN: 1873-4286, 1381-6128), 2009 Jul; 15(21): 2414-2429.
Impact Factor: 4.414
View Export to BibTeX Export to EndNote
Santulli G, Ciccarelli M, Palumbo G, Campanile A, Galasso G, Ziaco B, Altobelli GG, Cimini V, Piscione F, D'Andrea LD, Pedone C, Trimarco B, Iaccarino G
* In vivo properties of the proangiogenic peptide QK (417 views)
J Transl Med (ISSN: 1479-5876, 1479-5876electronic, 1479-5876linking), 2009 Jun 8; 7: 41-41.
Impact Factor: 3.407
View Export to BibTeX Export to EndNote
Cho WG, Albuquerque RJ, Kleinman ME, Tarallo V, Greco A, Nozaki M, Green MG, Baffi JZ, Ambati BK, De Falco M, Alexander JS, Brunetti A, De Falco S, Ambati J
* Small interfering RNA-induced TLR3 activation inhibits blood and lymphatic vessel growth (421 views)
P Natl Acad Sci Usa (ISSN: 0027-8424, 1091-6490, 0027-8424print), 2009 Apr 28; 106(17): 7137-7142.
Impact Factor: 9.432
View Export to BibTeX Export to EndNote
Cittadini A, Monti MG, Castiello MC, D'Arco E, Galasso G, Sorriento D, Saldamarco L, De Paulis A, Napoli R, Iaccarino G, Saccà L
* Insulin-like growth factor-1 protects from vascular stenosis and accelerates re-endothelialization in a rat model of carotid artery injury (466 views)
J Thromb Haemost Journal Of Thrombosis And Haemostasis (ISSN: 1538-7933), 2009; 7(11): 1920-1928.
Impact Factor: 6.069
View Export to BibTeX Export to EndNote
Ponticelli S, Marasco D, Tarallo V, Albuquerque RJC, Mitola S, Takeda A, Stassen J, Presta M, Ambati J, Ruvo M, De Falco S
* Modulation of Angiogenesis by a Tetrameric Tripeptide That Antagonizes Vascular Endothelial Growth Factor Receptor (615 views)
Jbc Papers (ISSN: 0021-9258, 1083-351x, 0021-9258linking), 2008 Dec 5; 283(49): 34250-34259.
Impact Factor: 5.52
View Export to BibTeX Export to EndNote
Dudar GK, D'Andrea LD, Di Stasi R, Pedone C, Wallace JL
* A vascular endothelial growth factor mimetic accelerates gastric ulcer healing in an iNOS-dependent manner (923 views)
Am J Physiol Gastrointest Liver Physiol American Journal Of Physiology Gastrointestinal And Liver Physiology (ISSN: 0193-1857), 2008 Sep; 295(2): G374-G381.
Impact Factor: 3.587
View Export to BibTeX Export to EndNote
Ponticelli S, Takeda A, Mitola S, Stassen J, Presta M, Ambati J, Ruvo M, De Falco S, Marasco D
* Angiogenesis modulation: identification of tetrameric tripeptide as inhibitor of VEGFR-1 by the screening of peptide combinatiorial libraries (351 views)
J Pept Sci (ISSN: 1075-2617, 1099-1387, 1075-2617print), 2008 Sep; 14(8): N/D-N/D.
Impact Factor: 1.654
View Export to BibTeX Export to EndNote
Di Stasi R, Capasso D, Diana D, Fattorusso R, Pedone C, D'Andrea LD
* Vascular Endothelial Growth Factor (VEGF) and its receptors: key regulators of angiogenesis (290 views)
J Pept Sci (ISSN: 1075-2617, 1099-1387, 1075-2617print), 2008 Sep; 14(8): N/D-N/D.
Impact Factor: 1.654
View Export to BibTeX Export to EndNote
Leese MP, Jourdan FL, Gaukroger K, Mahon MF, Newman SP, Foster PA, Stengel C, Regis-Lydi S, Ferrandis E, Di Fiore A, De Simone G, Supuran CT, Purohit A, Reed MJ, Potter BVL
* Structure-activity relationships of C-17 cyano-substituted estratrienes as anticancer agents (464 views)
J Med Chem (ISSN: 0022-2623, 1520-4804, 0022-2623print), 2008 Mar 13; 51(5): 1295-1308.
Impact Factor: 4.898
View Export to BibTeX Export to EndNote
Diana D, Ziaco B, Colombo G, Scarabelli G, Romanelli A, Fedone C, Fattorusso R, D'Andrea LD
* Structural determinants of the unusual helix stability of a de novo engineered vascular endothelial growth factor (VEGF) mimicking peptide (470 views)
Chemistry (ISSN: 0947-6539, 1521-3765, 1521-3765electronic), 2008; 14(14): 4164-4166.
Impact Factor: 5.454
View Export to BibTeX Export to EndNote
Sorriento D, Ciccarelli M, Santulli G, Campanile A, Altobelli GG, Cimini V, Galasso G, Astone D, Piscione F, Pastore L, Trimarco B, Iaccarino G
* The G-protein-coupled receptor kinase 5 inhibits NFκB transcriptional activity by inducing nuclear accumulation of IκBα (438 views)
P Natl Acad Sci Usa (ISSN: 0027-8424, 1091-6490, 0027-8424print), 2008; 105(46): 17818-17823.
Impact Factor: 9.38
View Export to BibTeX Export to EndNote
Costantino V, De Rosa C, Fattorusso E, Imperatore C, Mangoni A, Irace C, Maffettone C, Capasso D, Malorni L, Palumbo R, Pedone C
* Oreacerebrosides: Bioactive cerebrosides with a triunsaturated sphingoid base from the sea star Oreaster reticulatus (262 views)
Eur J Org Chem (ISSN: 1434-193x), 2007 Nov; (31): 5277-5283.
Impact Factor: 2.914
View Export to BibTeX Export to EndNote
Zannetti A, Fonti R, Iommelli F, Papaccioli A, Sommella J, Tortora G, Bianco R, Salvatore M, Del Vecchio S
* SPECT imaging of endoplasmic reticulum-mediated tumor response to gefitinib and erlotinib in lung cancer (424 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2007 Oct; 34: 277-309.
Impact Factor: 4.101
View Export to BibTeX Export to EndNote
Ntziachristos V, Cuénod CA, Fournier L, Balvay D, Pradel C, Siauve N, Clement O, Jouannot E, Lucidarme O, Vecchio SD, Salvatore M, Law B, Tung C-H, Jain RK, Fukumura D, Munn LL, Brown EB, Schellenberger E, Montet X, Weissleder R, Clerck ND, Postnov A
* Tumor Imaging (350 views)
Textbook Of In Vivo Imaging In Vertebrates (ISSN: 9780-4700), 2007 Jul 16; 1: 277-309.
Impact Factor: 1.148
View Export to BibTeX Export to EndNote
Del Gatto A, Zaccaro L, Grieco P, Novellino E, Zannetti A, Del Vecchio S, Iommelli F, Salvatore M, Pedone C, Saviano M
* Novel And Selective Alpha (v) Beta3 Receptor Peptide Antagonist: Design, Synthesis, And Biological Behavior (730 views)
J Med Chem (ISSN: 0022-2623, 1520-4804, 0022-2623print), 2006 Jun 1; 49(11): 3416-3420.
Impact Factor: 5.115
View Export to BibTeX Export to EndNote
Del Gatto A, D'Andrea LD, Zaccaro L, Saviano M, Pedone C, Benedetti E
* Engineering Peptides In Angiogenesis (418 views)
Biopolymers, 2006; 0: 215-216.
Impact Factor: 2.288
View Export to BibTeX Export to EndNote
D'Andrea LD, Iaccarino G, Fattorusso R, Sorriento D, Carannante C, Capasso D, Trimarco B, Pedone C
* Targeting angiogenesis: Structural characterization and biological properties of a de novo engineered VEGF mimicking peptide (657 views)
P Natl Acad Sci Usa (ISSN: 0027-8424, 1091-6490, 0027-8424print), 2005 Oct 4; 102(40): 14215-14220.
Impact Factor: 10.231
View Export to BibTeX Export to EndNote
Iaccarino G, Ciccarelli M, Sorriento D, Galasso G, Campanile A, Santulli G, Cipolletta E, Cerullo V, Cimini V, Altobelli GG, Piscione F, Priante O, Pastore L, Chiariello M, Salvatore F, Koch WJ, Trimarco B
* Ischemic neoangiogenesis enhanced by β2-adrenergic receptor overexpression: A novel role for the endothelial adrenergic system (380 views)
Circ Res (ISSN: 0009-7330, 1524-4571electronic), 2005; 97(11): 1182-1189.
Impact Factor: 9.408
View Export to BibTeX Export to EndNote
Salvatore M, Fonti R
* New frontiers of nuclear medicine (457 views)
Tumori (ISSN: 0300-8916, 0300-8916print, 0300-8916linking), 2002 May; 88(3): S60-S60.
Impact Factor: 0.267
View Export to BibTeX Export to EndNote
73 Records (70 excluding Abstracts).
Total impact factor: 315.268 (311.693 excluding Abstracts).
Total 5 year impact factor: 307.304 (302.671 excluding Abstracts).
Total impact factor: 315.268 (311.693 excluding Abstracts).
Total 5 year impact factor: 307.304 (302.671 excluding Abstracts).
843 views. Last view on Saturday 03 June 2023, 11:53:05
ibb.cnr.it
